Adjustment to adaptive deep brain stimulation
By monitoring brain signals and events and automatically adjusting electrical stimulation parameters through a closed-loop adaptive stimulation therapy system, the time and resource consumption problems of existing systems are solved, achieving more efficient and optimized electrical stimulation therapy.
Patent Information
- Application Number
- CN202580029079.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-26
- Filing Date
- 2025-04-01
- Publication Date
- 2026-11-17
AI Technical Summary
Existing electrostimulation therapy systems consume a significant amount of clinicians' time when adjusting electrostimulation parameters and cannot automatically adjust according to real-time changes in patients, resulting in increased power consumption and poor treatment outcomes.
The closed-loop adaptive stimulation therapy system monitors the patient's brain signals and events, and automatically adjusts electrical stimulation parameters, such as voltage or current amplitude, to ensure that the treatment runs within a steady-state window and reduce unnecessary electrical stimulation.
It improves the automation of electrical stimulation therapy, reduces the time clinicians spend manually adjusting, optimizes treatment outcomes, reduces power consumption, and minimizes side effects.
Smart Images

Figure CN123125017A_ABST
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 639,401, filed April 26, 2024, the entire contents of which are incorporated herein by reference. Technical Field
[0003] This disclosure relates in general to electrostimulation therapy. Background Technology
[0004] Medical devices can be external or implanted and can be used to deliver electrical stimulation therapy to various tissue sites in a patient to treat a variety of symptoms or conditions, such as chronic pain, tremor, Parkinson's disease, other movement disorders, epilepsy, urinary or fecal incontinence, sexual dysfunction, obesity, or gastroparesis. Medical devices can deliver electrical stimulation therapy via one or more leads, which include electrodes located near target sites associated with the patient's brain, spinal cord, pelvic nerves, peripheral nerves, or gastrointestinal tract. Therefore, electrical stimulation can be used for various therapeutic applications, such as deep brain stimulation (DBS), spinal cord stimulation (SCS), pelvic stimulation, gastric stimulation, or peripheral nerve field stimulation (PNFS).
[0005] Clinicians can select values for multiple programmable parameters to define the electrical stimulation therapy to be delivered to the patient by an implantable stimulator. For example, a clinician can select one or more electrodes for delivering stimulation, the polarity of each selected electrode, the voltage or current amplitude, pulse width, and pulse frequency as stimulation parameters. The set of parameters (such as a set including electrode combinations, electrode polarity, voltage or current amplitude, pulse width, and pulse frequency) can be referred to as a program in the sense that they define the electrical stimulation therapy to be delivered to the patient. Summary of the Invention
[0006] Generally, this disclosure describes apparatus, systems, and techniques for automating the programming and tuning of adaptive stimulation therapies (e.g., adaptive deep brain stimulation (aDBS)). This may include monitoring brain signals, stimulation parameter values, patient events, or other aspects related to the patient and the aDBS therapy. For example, the programming apparatus may be configured to monitor patient events and associated sensed bioelectrical signals (such as brain signals) to suggest and / or select thresholds that define the adaptive stimulation therapy. In this way, the system can utilize patient data to fine-tune parameters (such as thresholds) of the adaptive stimulation therapy that define how the system changes the therapy over time in response to sensed signals from the patient.
[0007] In some examples, the system may be configured to present a user interface that displays information related to aDBS therapy and / or brain signal monitoring. The system may include an external programming device that communicates with a medical device (e.g., an implantable medical device), and / or the medical device is configured to sense physiological signals, such as electrical signals originating from the patient's brain. The system may employ aspects of these signals to present information to the user and automate the selection of various parameters (such as values for one or more adaptive stimulation thresholds) used for subsequent sensing and / or delivery of stimulation. While aDBS is a non-limiting example therapy, the techniques disclosed herein can be applied to many forms of adaptive stimulation therapy that can be configured to treat other conditions and / or other anatomical structures of a patient.
[0008] External devices (e.g., external programmers) can be configured to automatically select various parameters defining the sensing and / or delivery of stimulation based on patient events and associated sensed physiological signals. The external device can select these parameters or ranges of their values, or present these selections to a user via a user interface for approval or confirmation. In some examples, the external programmer's user interface can control an implant (e.g., an implantable medical device) to deliver stimulation with varying parameters (such as varying amplitude) and sense the bioelectrical signals generated by that stimulation. An example parameter defining adaptive stimulation therapy could be one or more thresholds that, when met or exceeded, trigger the system to adjust one or more stimulation parameters defining the stimulation therapy. The system can correlate identified patient events (e.g., sensed events or user-input-indicated events) with sensed signals (e.g., local field potentials (LFP)) and derive characteristic values from the event information representing the sensed signals. The system can then identify suggested ranges of values, or even select values for one or more thresholds defining subsequent adaptive stimulation therapy. Therefore, this system can identify effective adaptive therapies for patients, such as aDBS, more quickly compared to more manual methods.
[0009] In one example, a system includes processing circuitry configured to: receive sensing data indicating brain bioelectrical signals sensed during delivery of brain stimulation therapy to a patient; receive event data indicating events experienced by the patient during delivery of the brain stimulation therapy; identify a subset of the sensing data based on the event data; determine a value range based on the subset of the sensing data and the event data that defines at least one threshold for subsequent brain stimulation therapy, the value range being determined to reduce the occurrence of the event during delivery of the subsequent brain stimulation therapy; and control a medical device to deliver the subsequent brain stimulation therapy according to the at least one threshold within the value range.
[0010] In another example, a method includes: receiving sensing data by a processing circuit indicating brain bioelectrical signals sensed during delivery of brain stimulation therapy to a patient; receiving event data by the processing circuit indicating events experienced by the patient during delivery of the brain stimulation therapy; identifying a subset of the sensing data by the processing circuit based on the event data; determining a range of values for at least one threshold defining a subsequent brain stimulation therapy based on the subset of the sensing data and the event data, the range of values being determined to reduce the occurrence of the event during delivery of the subsequent brain stimulation therapy; and controlling a medical device by the processing circuit to deliver the subsequent brain stimulation therapy according to the at least one threshold within the range of values.
[0011] In another example, a non-transitory computer-readable medium includes instructions that, when executed, control processing circuitry to: receive sensing data indicating brain bioelectrical signals sensed during delivery of brain stimulation therapy to a patient; receive event data indicating events experienced by the patient during delivery of the brain stimulation therapy; identify a subset of the sensing data based on the event data; determine a range of values for at least one threshold defining a subsequent brain stimulation therapy based on the subset of the sensing data and the event data, the range of values being determined to reduce the occurrence of the event during delivery of the subsequent brain stimulation therapy; and control a medical device to deliver the subsequent brain stimulation therapy according to the at least one threshold within the range of values.
[0012] Details of one or more examples of the technology disclosed herein are set forth in the accompanying drawings and the following description. Other features, objectives, and advantages of these technologies will be apparent from the specification, drawings, and claims. Attached Figure Description
[0013] Figure 1 This is a conceptual diagram illustrating an example system comprising an implantable medical device (IMD) configured to deliver a DBS to a patient, according to an example of the technology of this disclosure.
[0014] Figure 2 Examples of techniques according to this disclosure for delivering DBS therapy Figure 1 A block diagram of an example IMD.
[0015] Figure 3 Examples of techniques according to this disclosure for controlling the delivery of DBS therapy Figure 1 A block diagram of the external programmer.
[0016] Figure 4 This is a concept diagram illustrating a sample home screen used for navigation within the user interface.
[0017] Figure 5 This is a concept diagram illustrating an example screen used to select an adaptive therapy mode.
[0018] Figure 6 This is a conceptual diagram illustrating an example screen used to select one or more thresholds that define an adaptive DBS (aDBS) therapy.
[0019] Figure 7 This is a flowchart illustrating an example technique for selecting an adaptive therapy mode for aDBS.
[0020] Figure 8 This is a conceptual diagram illustrating an example screen used to track LFP power and stimulation amplitude during aDBS therapy.
[0021] Figure 9 This is a conceptual diagram illustrating a sample screen that displays sample event information associated with a corresponding patient event.
[0022] Figure 10 This is a conceptual diagram illustrating a sample screen that displays information about a single sample patient event and related events.
[0023] Figure 11A and Figure 11B It is a chart of example thresholds and value ranges determined based on event information.
[0024] Figure 12 This is a flowchart illustrating an example technique for determining and displaying the value range of one or more thresholds that define aDBS therapy.
[0025] Figure 13 This is a flowchart illustrating an example technique for selecting values for one or more thresholds that define an aDBS therapy based on event information.
[0026] Figure 14 Examples include coupling to via a network. Figure 1 A and Figure 1 Block diagram of an example system of an implantable medical device and an external device (such as a server) and one or more computing devices, shown in B. Detailed Implementation
[0027] This disclosure describes example apparatus, systems, and techniques for programming adaptive stimulation therapy, wherein the system can automatically select one or more parameters defining the adaptive stimulation therapy based on signals sensed from a patient. The patient may have one or more symptoms that can be treated with electrical stimulation therapy. For example, the patient may have a brain dysfunction (such as Parkinson's disease, Alzheimer's disease) or another type of motor disorder. Deep brain stimulation (DBS) can be an effective treatment for reducing symptoms associated with such disorders. However, manually determining the appropriate stimulation parameters to define an effective electrical stimulation therapy can be time-consuming for clinicians. Typically, clinicians may need to manually identify each parameter defining the electrical stimulation therapy. Furthermore, DBS is typically delivered continuously to the patient in an open-loop manner. Not only does this open-loop delivery consume more battery power due to delivering stimulation when the patient does not require it, but the system cannot adjust the stimulation parameters to provide a more targeted therapy as the patient's condition changes over time or under certain conditions. Additionally, it can be challenging for clinicians to identify patient events (e.g., falls) and patient symptoms, and what types of adjustments can be made over time to improve the therapy. Even if the system can detect indications of these patient changes, this introduces another parameter that clinicians will need to identify as part of the initial setup of the patient’s therapy and / or throughout the patient’s therapy delivery.
[0028] In closed-loop adaptive stimulation therapy protocols, one or more parameters defining the stimulation can be automatically adjusted in response to signals sensed from the patient. For example, the sensed signal, such as an LFP signal, can be compared to one or more thresholds. In response to a characteristic value of the LFP signal (e.g., the spectral power of a specific frequency or band of the LFP signal) meeting or exceeding a threshold, the system can automatically adjust the stimulation parameter value (e.g., amplitude value) to bring that characteristic of the LFP signal back below (or above) the threshold. In some examples, clinicians may initially select values for one or more thresholds. If two thresholds are used, this creates a “steady-state window” for the sensed signal. Other thresholds may also be used, such as one or more limits that define a “treatment window” that defines acceptable stimulation parameter values (e.g., amplitude) for stimulation. For some patients, medication may be prescribed in addition to stimulation therapy. This medication can alter how the patient perceives symptoms and / or responds to stimulation therapy. If clinicians initially set thresholds when the patient is not taking medication, these thresholds may be inaccurate when the patient is taking medication. Threshold determination may be more accurate when a patient is taking medication, but this may not be possible in a clinical setting or when a patient is initially fitted with therapy in other ways. Clinicians and / or patients can adjust these thresholds over time, but this manual adjustment is often based on a “best guess” made from the patient’s subjective feedback. Furthermore, patients may not accurately communicate what they perceive as symptoms, or the timing of side effects experienced during therapy due to inappropriate stimulus settings. Even if clinicians adjust the thresholds in the right direction, the magnitude of this threshold change may be inappropriate and require additional adjustments over time. During this period of manual adjustment, the patient may be experiencing a therapy that is less effective than other possible treatments.
[0029] As described herein, various devices, systems, and technologies enable the partial or full automation of programming and management of DBS therapy and / or brain sensing for patients. For example, the systems described herein can be configured to sense and record brain signals associated with brain disorders (e.g., electroencephalogram (EEG) signals, LFP signals, or other brain signals). In some examples, the system can also determine a range or value, or specific value, of one or more thresholds for the sensed signals and / or stimulation parameters to define adaptive stimulation (e.g., closed-loop therapy). The system can also display selections and / or information corresponding to the recorded brain signals for a user (e.g., a clinician) to view, select, and / or confirm. In some examples, the system can automatically select one or more appropriate thresholds based on one or more characteristics of the recorded brain signals. In some examples, the system can receive user input specifying or adjusting the selected adaptive mode and one or more appropriate thresholds.
[0030] For example, the system can track patient events occurring during the delivery of adaptive stimulation therapy and the associated sensed brain signals of these patient events. Example patient events include unwanted symptoms and / or side effects perceived by the patient, which may occur due to inappropriate therapy (e.g., stimulation that is stronger than needed). The system can receive user input identifying these patient events and / or automatically detect patient events by sensing signals indicating patient events (e.g., accelerometer readings indicating patient movement, a patient falling, or brain signals indicating symptoms or side effects). The system can then also correlate the brain signals sensed during these time periods corresponding to the patient events. The system can then calculate characteristic values of the sensed brain signals and, based on the actual sensed signals corresponding to the patient events, determine whether the current threshold is valid, whether the threshold needs to be changed, generate a range of threshold values, and / or select a different threshold.
[0031] These various features of the systems and technologies described herein offer advantages over other systems and improve system functionality and patient outcomes. For example, the system can automatically track patient events and associated sensed signals to automatically identify thresholds for adaptive stimulation and / or other stimulation parameters that can alleviate symptoms and / or side effects, thereby reducing the time clinicians need to manually monitor sensed signals and find appropriate parameters. The system can still present this information for clinicians to manually set thresholds that conform to these recommendations or automatically select thresholds. This process can also occur over hours, days, weeks, or even longer to obtain more accurate information than is available solely in the clinic. These automatic selections associated with aDBS reduce the time spent by clinicians, improve the consistency of parameter selection, and improve patient outcomes by increasing the efficacy of therapeutic stimuli and reducing side effects.
[0032] Figure 1 This is a conceptual diagram illustrating an example system 100 including an implantable medical device (IMD) 106 configured to deliver adaptive deep brain stimulation to a patient 112. The DBS can be adaptive (aDBS) in the sense that the IMD 106 can adjust, increase, or decrease the values of one or more stimulation parameters defining the DBS in response to changes in patient activity or movement, the severity of one or more symptoms of the patient's condition, the presence of one or more side effects caused by the DBS, or one or more sensed signals from the patient. For example, the system 100 can use one or more sensed signals from the patient as control signals, causing the IMD 106 to adjust the magnitude of one or more parameters of the electrical stimulation in response to the magnitude or change of the magnitude of one or more sensed signals. This process enables the system 100 to automatically adjust the stimulation therapy in response to changes in the patient's condition, such as changes in brain activity indicating the level of therapeutic efficacy.
[0033] Example therapy system 100 includes a medical device programmer 104, an implantable medical device (IMD) 106, a lead extension 110, and leads 114A and 114B having corresponding sets of electrodes 116 and 118. Figure 1 In the illustrated example, electrodes 116 and 118 of leads 114A and 114B are positioned to deliver electrical stimulation to tissue sites within brain 120, such as the deep brain region beneath the dura mater of patient 112's brain 120. In some examples, delivering stimulation to one or more regions of brain 120 (such as the subthalamic nucleus, globus pallidus, or thalamus) could be an effective treatment for managing movement disorders such as Parkinson's disease. Some or all of electrodes 116 and 118 may also be positioned to sense brain bioelectrical signals within patient 112's brain 120. In some examples, some electrodes 116 and 118 may be configured to sense brain bioelectrical signals, and other electrodes 116 and 118 may be configured to deliver adaptive electrical stimulation to brain 120. In other examples, all electrodes 116 and 118 are configured to sense brain bioelectrical signals and deliver adaptive electrical stimulation to brain 120.
[0034] IMD 106 includes a therapy module (e.g., which may include processing circuitry, signal generation circuitry, or other circuitry configured to perform functions attributed to IMD 106), which includes a stimulation generator configured to generate and deliver electrical stimulation therapy to patient 112 via a subset of electrodes 116, 118 of leads 114A and 114B, respectively. The subset of electrodes 116, 118 used to deliver electrical stimulation to patient 112, and in some cases, the polarity of the subset of electrodes 116, 118, may be referred to as a stimulating electrode combination. As described in further detail below, a stimulating electrode combination may be selected (e.g., based on bioelectrical signal information and patient condition) for a specific patient 112 and target tissue site. This set of electrodes 116, 118 includes at least one electrode and may include multiple electrodes. In some examples, the multiple electrodes 116 and / or 118 may have complex electrode geometries, such that two or more electrodes are located at different positions around the periphery of the respective leads.
[0035] According to some techniques of this disclosure, system 100 delivers electrical stimulation therapy via IMD 106, the electrical stimulation therapy being defined by one or more parameters (such as voltage or current amplitude) that adjust in response to signal deviations from a range defined by a steady-state window (e.g., a window defined by one or more thresholds, such as a lower threshold and an upper threshold, with which brain signals are compared). The steady-state window can be used as part of an adaptive stimulation pattern for adjusting the stimulation therapy over time. In some examples, system 100 may change other parameters in response to sensed signals (such as stimulation pulse frequency, pulse burst duration, pulse burst frequency, duty cycle, or electrode combination).
[0036] In some examples, patient 112 is taking medications designed to control one or more symptoms of Parkinson's disease, such as tremor or rigidity caused by Parkinson's. These medications include extended-release dopamine agonists; conventional dopamine agonists; controlled-release carbidopa / levodopa (CD / LD); and conventional CD / LD, entacapone, rasagiline, selegiline, and amantadine. Typically, to establish upper and lower thresholds for the steady-state window, the patient has discontinued the medication; that is, upper and lower thresholds are set when the patient is not taking medication intended to alleviate these symptoms. Patients can be considered as not taking medication if: for extended-release dopamine agonists, the patient has not taken medication for at least approximately 72 hours prior to the time specified for the upper limit threshold; for conventional dopamine agonists and controlled-release CD / LDs, the patient has not taken medication for at least approximately 24 hours; and for conventional CD / LDs, entacapone, rasagiline, selegiline, and amantadine, the patient has not taken medication for at least approximately 12 hours. If the stimulation only inhibits brain signals (e.g., LFP signals), the system 100 can measure these brain signals for various values of the stimulation parameters without external input. Once the upper and lower thresholds are established, the system 100 can identify when the drug's effect wears off, as the brain signal will cross either the lower or upper threshold. In response to identifying a brain signal crossing a threshold, the system 100 can activate electrical stimulation or adjust the amplitude or intensity of the electrical stimulation to restore the brain signal amplitude back to between the lower and upper thresholds, thereby alleviating symptoms again. Programmer 104 or IMD 106 can initially set lower and upper thresholds and adjust one or both thresholds over time. Programmer 104 or IMD 106 can also determine and display information related to the amount of time the stimulus amplitude is above, below, or between these thresholds. The system can be configured to determine frequency, adaptive mode, and one or more thresholds based on bioelectrical (or other) signals sensed when the patient is receiving and / or not receiving drug treatment. Whether the patient is receiving medication may influence which adaptive mode or threshold is used to adjust subsequent therapy.
[0037] As described in this article, “relief” or “suppression” of a patient’s symptoms refers to the degree to which one or more of the patient’s symptoms are completely or partially alleviated. In one example, a clinician refers to the Unified Parkinson’s Disease Rating Scale (UPDRS) or the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) to determine the severity of one or more symptoms of Parkinson’s disease in patient 112. The discussion on the application of MDS-UPDRS is provided by the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results, C. Goetz et al., Movement Disorders, Vol. 23, No. 15, pp. 2129-2170 (2008), the full text of which is incorporated herein by reference.
[0038] In some examples, system 100 may be configured to determine an upper threshold of a steady-state window when the patient is not taking medication and when electrical stimulation therapy is delivered to the brain 120 of patient 112 via IMD 106. In one example, system 100 determines the time point at which increasing the magnitude of one or more parameters defining the electrical stimulation therapy (such as voltage amplitude or current amplitude) begins to cause one or more side effects in patient 112. For example, system 100 may gradually increase the magnitude of one or more parameters defining the electrical stimulation therapy (such as amplitude) and determine the time point at which a further increase in the magnitude of one or more parameters defining the electrical stimulation therapy causes a perceptible side effect in patient 112. As described herein, IMD 106 may sense the LFP during this process and display an LFP signal and / or LFP signal magnitude that may correspond to a corresponding threshold. In this way, system 100 may automatically determine these thresholds.
[0039] As described herein, system 100 can also determine a lower threshold of the steady-state window when the patient discontinues medication and when the electrical stimulation therapy is delivered to the brain 120 of patient 112 via IMD 106. In one example, system 100 determines the time point at which reducing the magnitude of one or more parameters defining the electrical stimulation therapy (such as amplitude) causes one or more symptoms of patient 112 to break through. This symptom break-through may refer to the recurrence of at least some symptoms that were substantially suppressed up to the relapse time point due to the reduction in the magnitude of one or more electrical stimulation therapy parameters. For example, system 100 may gradually reduce the magnitude of one or more parameters defining the electrical stimulation therapy and determine the time point at which symptoms of Parkinson's disease appear in patient 112, as measured by a sudden increase in the patient 112's score in tremor or rigidity, as defined by UPDRS or MDS-UPDRS. In another example, system 100 measures physiological parameters of patient 112 associated with one or more symptoms of patient 112's disease (e.g., patient 112's wrist flexion) and determines the time point at which a further reduction in the magnitude of one or more parameters defining the electrical stimulation therapy causes a sudden exacerbation of one or more symptoms of patient 112's disease (e.g., patient 112 begins to experience inability to flex the wrist). Although the initial threshold for the steady-state window can be determined when patient 112 discontinues the medication, in some examples, threshold determination may be more effective when patient 112 is taking the medication. By monitoring patient events and sensed brain signals over time during therapy delivery, thresholds can be selected to more appropriately account for patient medication consumption, which may not be achievable through manual identification during clinical visits.
[0040] At a value defining one or more parameters of the electrical stimulation therapy (at which a further decrease in the value of one or more parameters of the electrical stimulation therapy causes a sudden exacerbation of one or more symptoms of the patient 112's disease), system 100 may measure the magnitude of the patient 112's signal and set that magnitude as a lower threshold of a steady-state window. In some examples, system 100 may select the lower threshold of the steady-state window to be a predetermined amount (e.g., 5% or 10% higher) higher than the magnitude at which the patient 112's symptoms first appear during a decrease in the magnitude of one or more electrical stimulation parameters, to prevent the patient 112's symptoms from recurring during subsequent use.
[0041] In another example, system 100 may set a lower threshold by first ensuring that the patient discontinues medication treating one or more symptoms. In this example, system 100 delivers electrical stimulation whose value of one or more parameters is approximately equal to the upper threshold of the treatment window. In some examples, system 100 delivers electrical stimulation whose value of one or more parameters is slightly lower than the magnitude that would cause side effects in patient 112. Typically, this results in a greater reduction in one or more symptoms of patient 112's condition and therefore a greater reduction in signal. At this magnitude of one or more parameters, system 100 measures the magnitude of patient 112's signal and sets this magnitude as the lower threshold of the steady-state window via external programmer 104. In some examples, system 100 may select the value of the lower threshold of the steady-state window to be a predetermined amount (e.g., 5% or 10% higher) higher than the magnitude at which patient 112 experiences these symptoms, to prevent the recurrence of patient 112's symptoms during subsequent use.
[0042] System 100 can monitor one or more signals from the patient for selecting and / or adjusting one or more parameters defining the stimulus in a closed-loop manner. In one example, the signal is the patient's bioelectrical signal, such as brain signals (e.g., LFP) with frequencies in the patient's brain's beta and / or gamma bands. For example, the monitored signal could be the power of the corresponding beta and / or gamma band (determined based on which frequency changes during stimulus delivery and / or under the influence of medication). In yet another example, the signal could be a signal indicative of the patient's physiological parameters, such as the severity of the patient's symptoms, the patient's mobility, the patient's position, the patient's respiratory function, heart rate, or the patient's activity level. System 100 can use a single signal or a combination of different signals to initially select and / or adjust one or more parameters defining subsequent stimulation therapy. System 100 can be configured via IMD 106 to deliver electrical stimulation to the patient, wherein one or more parameters defining the electrical stimulation are proportional to the magnitude of the monitored signal or adjusted in response to the magnitude of the monitored signal exceeding one or more thresholds.
[0043] System 100 can be configured to treat one or more patient conditions, such as motor disorders, neurodegenerative damage, mood disorders, or epilepsy in patient 112. Patient 112 is typically a human patient. However, in some cases, the therapeutic system 100 may be applied to other mammalian or non-mammal, non-human patients. While this document primarily refers to motor disorders and neurodegenerative damage, in other examples, the therapeutic system 100 may provide therapy to manage symptoms of other patient conditions, such as, but not limited to, epilepsy (e.g., seizures) or mood (or psychological) disorders (e.g., major depressive disorder (MDD), bipolar disorder, anxiety disorder, post-traumatic stress disorder, dysthymia, and obsessive-compulsive disorder (OCD)). At least some of these disorders may manifest as motor behaviors in one or more patients. As described herein, motor disorders or other neurodegenerative damage may include symptoms such as impaired muscle control, motor impairment, or other motor problems such as stiffness, spasticity, bradykinesia, rhythmic hyperkinesia, non-rhythmic hyperkinesia, and akinesia. In some cases, motor disorders may be symptoms of Parkinson's disease. However, movement disorders can be attributed to other patient conditions.
[0044] In some examples, the bioelectrical signals sensed within brain 120 may reflect changes in current generated by the sum of potential differences across the entire brain tissue. Examples of brain bioelectrical signals include, but are not limited to, electrical signals generated by local field potentials (LFPs) sensed in one or more regions of brain 120, such as electroencephalogram (EEG) signals or electrocorticography (ECoG) signals. However, local field potentials may include a wider variety of electrical signals within the brain 120 of patient 112.
[0045] In some examples, brain bioelectrical signals for selecting a combination of stimulation electrodes can be sensed in the same region of brain 120 as the target tissue site used for electrical stimulation. As previously indicated, these tissue sites may include tissue sites within anatomical structures (such as the thalamus, subthalamic nucleus, or globus pallidus of brain 120), as well as other target tissue sites. Specific target tissue sites and / or regions within brain 120 can be selected based on the patient's condition. Therefore, in some examples, the electrodes used to deliver electrical stimulation may be different from the electrodes used to sense brain bioelectrical signals. In other examples, the same electrodes may be used for both delivering electrical stimulation and sensing brain signals. However, this configuration may require system 100 to switch between stimulation generation and sensing circuitry and may reduce the time during which system 100 can sense brain signals.
[0046] The electrical stimulation generated by the IMD 106 can be configured to manage various disorders and conditions. In some examples, the stimulation generator of the IMD 106 is configured to generate electrical stimulation pulses via electrodes of a selected combination of stimulation electrodes and deliver such pulses to the patient 112. However, in other examples, the stimulation generator of the IMD 106 can be configured to generate and deliver continuous wave signals, such as sine waves or triangular waves. In either case, the stimulation generator within the IMD 106 can generate electrical stimulation therapy for DBS according to a therapy procedure selected at a given time in the therapy. In examples where the IMD 106 delivers electrical stimulation in the form of stimulation pulses, the therapy procedure may include a set of therapy parameter values (e.g., stimulation parameters), such as the combination of stimulation electrodes used to deliver stimulation to the patient 112, the pulse frequency, the pulse width, and the current or voltage amplitude of the pulse. As previously noted, the electrode combination may indicate the specific electrodes 116, 118 selected for delivering the stimulation signal to the tissue of the patient 112, and the corresponding polarity of the selected electrodes.
[0047] The IMD 106 can be implanted in a subcutaneous pouch above the clavicle, or alternatively, above or within the skull 122, or at any other suitable site within the patient 112. Generally, the IMD 106 is constructed of a biocompatible material resistant to corrosion and degradation by bodily fluids. The IMD 106 may include an airtight housing to substantially encapsulate components such as the processor, therapy module, and memory.
[0048] like Figure 1 As shown, the implanted lead extension 110 is coupled to the IMD 106 via a connector 108 (also referred to as the connector block or connector of the IMD 106). Figure 1 In the example, the lead extension 110 extends from the implantation site of the IMD 106 and crosses along the neck of the patient 112 to the skull 122 of the patient 112 to enter the brain 120. Figure 1 In the example shown, leads 114A and 114B (collectively, “leads 114”) are implanted in the right and left hemispheres of patient 112, respectively, to deliver electrical stimulation to one or more regions of brain 120, which may be selected based on patient symptoms or disorders controlled by therapy system 100. However, specific target tissue sites and stimulation electrodes for delivering stimulation to those target tissue sites may be selected, for example, based on identified patient behavior and / or other sensed patient parameters. Other implantation sites for leads 114 and IMD 106 are envisioned. For example, in some examples, IMD 106 may be implanted on or within skull 122. Alternatively, leads 114 may be implanted within the same hemisphere, or IMD 106 may be coupled to a single lead implanted in a single hemisphere.
[0049] Existing lead assemblies include axial leads carrying annular electrodes positioned at different axial locations and so-called "paddle" leads carrying planar array electrodes. The selection of electrode combinations within axial leads, paddle leads, or between two or more different leads presents a challenge for clinicians. In some examples, more complex lead array geometries can be used.
[0050] Although lead 114 is in Figure 1 The lead 114 is shown coupled to a common lead extension 110, but in other examples, the lead 114 may be coupled to the IMD 106 via a separate lead extension or directly coupled to the connector 108. The lead 114 may be positioned to deliver electrical stimulation to one or more target tissue sites within the brain 120 to manage patient symptoms associated with motor dysfunction in the patient 112. The lead 114 may be implanted to position the electrodes 116, 118 at desired locations within the brain 120 through corresponding holes in the skull 122. The lead 114 may be placed at any location within the brain 120 such that the electrodes 116, 118 can provide electrical stimulation to target tissue sites within the brain 120 during treatment. For example, the electrodes 116, 118 may be surgically implanted beneath the dura mater of the brain 120 or within the cerebral cortex of the brain 120 through a burr hole in the skull 122 of the patient 112, and electrically coupled to the IMD 106 via one or more leads 114.
[0051] exist Figure 1 In the example shown, electrodes 116 and 118 of lead 114 are shown as ring electrodes. Ring electrodes can be used in aDBS applications because they are relatively easy to program and can deliver an electric field to any tissue adjacent to electrodes 116 and 118. In other examples, electrodes 116 and 118 may have different configurations. For example, in some examples, at least some of the electrodes 116 and 118 of lead 114 may have a complex electrode array geometry capable of generating a shaped electric field. The complex electrode array geometry may include multiple electrodes (e.g., partially ring or segmented electrodes) around the outer periphery of each lead 114, rather than a single ring electrode. In this way, electrical stimulation can be directed from lead 114 in a specific direction to enhance therapeutic efficacy and reduce potential adverse side effects due to stimulation of large amounts of tissue. In some examples, the housing of IMD 106 may include one or more stimulation and / or sensing electrodes. In alternative examples, lead 114 may have, in addition to, Figure 1 Shapes other than the elongated cylinder shown. For example, lead 114 can be a paddle lead, a spherical lead, a flexible lead, or any other type of shape that is effective in treating patient 112 and / or minimizing the invasiveness of lead 114.
[0052] exist Figure 1In the example shown, IMD 106 includes a memory for storing multiple therapy procedures, each with a defined set of therapy parameter values. In some examples, IMD 106 can select a therapy procedure from the memory based on various parameters, such as sensed patient parameters and identified patient behaviors. IMD 106 can generate electrical stimulation based on the selected therapy procedure to manage patient symptoms associated with movement disorders.
[0053] External programmer 104 wirelessly communicates with IMD 106 as needed to provide or retrieve treatment information. Programmer 104 is an external computing device that a user (e.g., a clinician and / or patient 112) can use to communicate with IMD 106. For example, programmer 104 could be a clinician programmer, which the clinician uses to communicate with IMD 106 and program one or more therapy procedures for IMD 106. Alternatively, programmer 104 could be a patient programmer, which allows patient 112 to select programs and / or view and modify therapy parameters. Clinician programmers may include more programming features than patient programmers. In other words, only clinician programmers may allow for more complex or sensitive tasks to prevent untrained patients from making unintended changes to IMD 106. Programmer 104 can be any type of device configured to communicate with IMD 106, such as a smartwatch, handheld computer, mobile device, charger, or any other device.
[0054] When programmer 104 is configured for use by a clinician, it can be used to send initial programming information to IMD 106. This initial information may include hardware information such as the type and electrode arrangement of leads 114, the location of leads 114 within brain 120, the configuration of electrode arrays 116, 118, an initial procedure defining therapeutic parameter values, and any other information the clinician wishes to program into IMD 106. Programmer 104 may also be able to perform functional tests (e.g., measuring the impedance of electrodes 116, 118 of leads 114). As a supplement to or alternative to programmer 104, various external computing devices may perform any functionality of programmer 104. These external computing devices may be networked devices and communicate directly with or via programmer 104 with IMD 106.
[0055] Clinicians can also store therapeutic procedures within IMD 106 using programmer 104. During a programming session, system 100 can identify one or more therapeutic procedures that provide effective treatment to patient 112 to address symptoms associated with the patient's condition, and in some cases, symptoms specific to one or more different patient states (such as sleep, movement, or rest). For example, system 100 can select one or more combinations of stimulation electrodes to deliver stimulation to brain 120. During a programming session, system 100 can evaluate the efficacy of a particular procedure based on feedback provided by the clinician, patient 112, or based on one or more physiological parameters of patient 112 (e.g., muscle activity, muscle tone, stiffness, tremor, etc.). Alternatively, patient behavior identified based on video information can be used as feedback during the initial and subsequent programming sessions.
[0056] Programmer 104 can also be configured for use by patient 112. When configured as a patient programmer, programmer 104 may have limited functionality (compared to a clinician programmer) to prevent patient 112 from altering critical functionality of IMD 106 or applications that may be harmful to patient 112. Thus, programmer 104 may only allow patient 112 to adjust the values of certain therapeutic parameters or set the available range of values for specific therapeutic parameters. When programmer 104 is configured for use by patient 112 (e.g., a patient programmer), programmer 104 may have limited adjustments and / or datasets available to the user compared to a clinician programmer. In this way, the patient programmer version prevents the patient from making adverse changes to the therapy but allows the patient to make some adjustments to the therapy as needed.
[0057] Programmer 104 may also provide indications to patient 112 when treatment is being delivered, when patient input triggers a treatment change, or when the power supply within programmer 104 or IMD 106 needs to be replaced or recharged. For example, programmer 112 may include alarm LEDs that can send messages to patient 112 via programmer display, generate audible or haptic cues to confirm receipt of patient input, such as indicating patient status or manual modification of treatment parameters.
[0058] The therapy system 100 can be implemented to provide chronic stimulation therapy to patient 112 over a period of months or years. However, system 100 can also be used on a trial basis to evaluate the therapy before full implantation. If implemented intermittently, some components of system 100 may not be implanted in patient 112. For example, patient 112 may be fitted with an external medical device, such as a trial stimulator, instead of IMD 106. The external medical device may be coupled to a percutaneous lead or implanted lead via a percutaneous extension. If the trial stimulator instructs the DBS system 100 to provide effective treatment to patient 112, the clinician may implant a chronic stimulator in patient 112 for relatively long-term treatment.
[0059] Although IMD 104 is described as delivering electrical stimulation therapy to brain 120, in other examples, IMD 106 may be configured to direct electrical stimulation to other anatomical areas of patient 112. In other examples, system 100 may include an implantable drug pump in addition to or instead of IMD 106. Furthermore, IMDs may provide other electrical stimulation, such as spinal cord stimulation, to treat movement disorders.
[0060] According to the technology of this disclosure, system 100 may define a steady-state window (e.g., one or more thresholds for an adaptive stimulation mode) and / or a treatment window for delivering aDBS to patient 112. System 100 may adaptively deliver electrical stimulation and adjust one or more parameters defining the electrical stimulation within a range of parameters defined by the upper and lower limits of the treatment window based on the activity of sensed bioelectrical signals (e.g., LFP signals, evoked resonant neural activity (ERNA), and EEG) within the steady-state window. For example, system 100 may adjust one or more parameters defining the electrical stimulation in response to a sensed signal falling below the lower threshold or exceeding the upper threshold of the steady-state window, but may not adjust one or more parameters defining the electrical stimulation such that they fall below the lower threshold or exceed the upper threshold of the treatment window.
[0061] In one example, external programmer 104 commands IMD 106 via instructions sent from external programmer 104 to IMD 106, causing IMD 106 to deliver electrical stimulation therapy via electrodes 116, 118 and via lead 114. As described above, in one example, the treatment window may define upper and lower limits for one or more parameters (e.g., amplitude or pulse width) that define the delivery of electrical stimulation therapy to patient 112. In other words, one or more limits of the treatment window may refer to limits that can adjust the values of parameters defining the stimulation. For example, the one or more parameters may include current amplitude (for a current control system) or voltage amplitude (for a voltage control system), pulse frequency or frequency, and pulse width. In an example of delivering electrical stimulation based on a “burst” of pulses or a series of electrical pulses defined by “on time” and “off time”, one or more parameters may also define one or more of the number of pulses in each burst, on time, and off time. In one example, the treatment window defines upper and lower limits for one or more parameters, such as upper and lower threshold values for the current amplitude of an electrical stimulation therapy (in a current control system) or upper and lower threshold values for the voltage amplitude of an electrical stimulation therapy (in a voltage control system). While the examples in this paper are generally given in relation to adjusting the voltage or current amplitude, the techniques described herein are equally applicable to steady-state windows and treatment windows using other parameters, such as, for example, pulse frequency or pulse width. Further detailed examples of specific implementations of treatment windows are provided below.
[0062] Typically, the patient programmer 104 may not have permission to adjust any thresholds or limits used for sensing or stimulation associated with aDBS. For example, the patient programmer 104 may only allow the patient to adjust stimulation parameter values within limits set by the clinician programmer. However, in other examples, the system 100 may provide aDBS by allowing the patient 112 to indirectly adjust the activation, deactivation, and magnitude of electrical stimulation, for example via the patient programmer 104, by adjusting the lower and upper thresholds of the steady-state window. In one example, the patient programmer 104 may be able to adjust the upper or lower threshold of the steady-state window by a small amount or percentage of the clinician-set value. In another example, by adjusting one or both thresholds of the steady-state window, the patient 112 may adjust the time point at which the sensed signal deviates from the steady-state window, thereby triggering the system 100 to adjust one or more parameters of the electrical stimulation within the parameter range defined by the lower and upper thresholds of the treatment window.
[0063] In some examples, the patient may provide feedback, for instance, via programmer 104, to adjust one or both thresholds of the steady-state window. For example, programmer 104 may provide an input mechanism where the patient can provide input indicating when the therapy is no longer effective (e.g., the patient detects symptoms) or when side effects are felt. Programmer 104 can then use this patient event data and associated sensed signals corresponding to that event to automatically adjust the thresholds of the steady-state window and / or the boundaries of the treatment window to reduce problems associated with patient feedback. In one example, programmer 104 may determine a range of appropriate values for one or more thresholds, within which the user can select a new threshold, or programmer 104 may automatically select a new threshold, which can be presented to the user for confirmation. In another example, programmer 104 may rerun the threshold determination process described herein or analyze stored sensed bioelectrical signals (e.g., LFP signals) and associated stimulus amplitudes to adjust one or more thresholds in an adaptive mode. In this manner, programmer 104 and / or IMD 106 can automatically adjust one or more thresholds of a steady-state window based on one or more physiological or bioelectrical signals of patient 112 sensed by IMD 106 and corresponding identified patient events. In response to deviations of the sensed signal from the patient outside the steady-state window, system 100 (e.g., IMD 106 or programmer 104) can automatically adjust the one or more parameters defined within a treatment window that defines a lower and upper threshold for one or more parameters (e.g., amplitude) of a defined electrical stimulation therapy delivered to the patient, in a manner proportional to the magnitude of the sensed signal. The adjustment of the one or more stimulation therapy parameters based on deviations of the sensed signal can be proportional to or inversely proportional to the magnitude of the signal.
[0064] Thus, in some examples, system 100 can adjust one or more parameters of electrical stimulation, such as voltage or current amplitude, within a treatment window via programmer 104 or IMD 106 based on patient input adjusting a steady-state window or based on one or more signals (such as sensed physiological parameters or sensed bioelectrical signals) or a combination of both or more of the above. Specifically, system 100 can automatically adjust the parameters of electrical stimulation in response to sensed signals satisfying one or more thresholds of the steady-state window and / or in response to patient input adjusting the steady-state window, provided that the values of the electrical stimulation parameters are constrained to remain within a range specified by an upper and lower limit of the treatment window. This range can be considered to include the upper and lower limits themselves.
[0065] In some examples of system 100 adjusting multiple parameters of electrical stimulation, system 100 may adjust at least one of voltage or current amplitude, stimulation frequency, pulse width, or electrode selection. In such examples, system 100 may set an order or sequence for adjusting these parameters (e.g., adjusting voltage or current amplitude, then adjusting stimulation frequency, and then adjusting electrode selection). In other examples, system 100 may randomly select the adjustment sequence of the multiple parameters. In any example, system 100 may adjust the value of a first parameter of the electrical stimulation. If the signal does not respond to the adjustment of the first parameter, system 100 may adjust the value of a second parameter of the electrical stimulation, and so on, until the signal returns to a steady-state window.
[0066] To adaptively adjust the parameters defining the DBS based on bioelectrical signals, for example, two or more electrodes 116, 118 of the IMD 106 may be configured to monitor bioelectrical signals (e.g., LFP signals) of the patient 112. In some examples, at least one of the electrodes 116, 118 may be disposed on the shell of the IMD 106 to provide a monopolar stimulation and / or sensing configuration. In one example, the bioelectrical signal may be selected as a signal within the β band of the patient 112's brain 120. For example, the bioelectrical signal within the β band of the patient 112 may be associated with one or more symptoms of Parkinson's disease in the patient 112. Generally, the bioelectrical signal within the β frequency of the patient 112 may be approximately proportional to the severity of the patient 112's symptoms. For example, as the tremor induced by Parkinson's disease increases, the bioelectrical signal within the β frequency of the patient 112 also increases (e.g., the magnitude of signal and / or spectral power). Furthermore, the bioelectrical signal within the β frequency is considered proportional, because system 100 can be configured such that an increase in the signal magnitude triggers system 100 to increase the delivered stimulus dose according to the disclosed technique. Similarly, as tremor induced by Parkinson's disease decreases, the bioelectrical signal within the β frequency of patient 112 also decreases (e.g., the magnitude of signal and / or spectral power), and this decrease triggers system 100 to decrease the delivered stimulus dose. However, in some examples, for some patients who require the system to respond in the opposite manner, these relationships between signal changes and symptom changes may be reversed. In some examples, for some patients, one or more frequencies in the γ band may respond to stimulation. This γ band responsiveness may occur with or without β-inhibition induced by the stimulus therapy.
[0067] In some examples, each sensor within the IMD 106 is an accelerometer, a bonded piezoelectric crystal, a mercury switch, or a gyroscope. In some examples, these sensors can provide signals indicative of a patient's physiological parameters, which then vary according to the patient's activity. For example, the device can monitor signals indicative of a patient's heart rate, electrocardiogram (ECG) morphology, electroencephalogram (EEG) morphology, respiratory rate, respiratory volume, core body temperature, subcutaneous temperature, or muscle activity. Any of these sensed signals can be used to identify patient events that may be symptoms and / or side effects for the patient.
[0068] In some examples, sensors generate signals based on both patient activity and patient position. For example, an accelerometer, gyroscope, or magnetometer may generate signals indicating the patient's activity and position. External programmer 104 can use this position-related information to determine whether it should perform adjustments to the treatment window.
[0069] For example, to identify body position, sensors such as accelerometers may be oriented substantially orthogonal to each other. In addition to being orthogonal to each other, each of the sensors used to detect the body position of patient 112 may also be substantially aligned with the axis of patient 112's body. When the accelerometers are aligned in this manner, for example, the magnitude and polarity of the DC component of the signal generated by the accelerometers indicate the patient's orientation relative to Earth's gravity, such as the body position of patient 112. Further information relating to determining patient position using orthogonally aligned accelerometers can be found in commonly assigned U.S. Patent No. 5,593,431 to Todd J. Sheldon, the entire contents of which are incorporated herein by reference.
[0070] Other sensors that can generate signals indicating the position of patient 112 include electrodes that generate signals such as electromyography (EMG) signals based on electrical activity within the muscles of patient 112, or bonded piezoelectric crystals that generate signals based on muscle contraction. The electrodes or bonded piezoelectric crystals may be implanted in the leg, hip, chest, abdomen, or back of patient 112 and wirelessly or via one or more leads to one or more of external programmer 104 and IMD 106. Alternatively, when IMD 106 is implanted in the hip, chest, abdomen, or back of patient 112, the electrodes may be integrated into the housing of IMD 106, or the piezoelectric crystal may be bonded to the housing. The signals generated by such sensors when implanted in these locations may vary based on the position of patient 112, for example, whether the patient is standing, sitting, or lying down.
[0071] Furthermore, the patient's position can affect their thoracic impedance. Therefore, the sensor may include an electrode pair comprising one electrode integrated into the housing of the IMD 106 and one of electrodes 116, 118 that generates a signal based on the patient's thoracic impedance, and the IMD 106 may detect the patient's position or a change in position based on this signal. In one example (not depicted), the electrodes of the electrode pair may be located on opposite sides of the patient's chest cavity. For example, the electrode pair may include electrodes located proximal to the patient's spine for delivery of SCS therapy, and the IMD 106, with the electrodes integrated in its housing, may be implanted in the patient's abdomen or chest. As another example, in addition to the lead 114 implanted in the patient's brain, the IMD 106 may also include electrodes implanted for detecting thoracic impedance. Position or a change in position can affect the delivery of DBS or SCS therapy to the patient 112 to treat any type of bioelectrical disorder and can also be used to detect patient sleep, as described herein.
[0072] Additionally, changes in the patient's position 112 can cause changes in the pressure of the patient's cerebrospinal fluid (CSF). Therefore, the sensor may include a pressure sensor coupled to one or more intrathecal or lateral ventricle catheters, or a pressure sensor wirelessly or via one of the leads 114 coupled to the IMD 106. CSF pressure changes associated with positional changes can be particularly evident within the patient's brain, for example, in intracranial pressure (ICP) waveforms.
[0073] Therefore, in some examples, instead of monitoring the patient's bioelectrical signals or otherwise, system 100 monitors one or more signals from sensors indicating the magnitude of physiological parameters of patient 112. When one or more signals from the sensors are detected to exceed the upper limit of a steady-state window, system 100 increases the stimulation at a maximum ramp rate determined by system 100 until one or more signals from the sensors return to within the steady-state window, or until the magnitude of the electrical stimulation reaches the upper limit of a treatment window determined by system 100. Similarly, when one or more signals from the sensors are detected to drop below the lower limit of a steady-state window, system 100 decreases the stimulation at a maximum ramp rate determined by system 100 until one or more signals from the sensors return to within the steady-state window, or until the magnitude of the electrical stimulation reaches the lower limit of a treatment window determined by system 100. When one or more signals from the sensors are detected to be within the threshold of the steady-state window, system 100 keeps the magnitude of the electrical stimulation constant.
[0074] This system 100 for delivering aDBS to a patient by monitoring physiological parameters offers advantages over other techniques that use bioelectrical signals as thresholds because the technology of this disclosure allows IMD to control the delivery of therapy using hysteresis. In other words, this system 100 can be configured to use the patient's physiological parameters (used alone or as a supplement to sensed bioelectrical signals) to create a closed-loop feedback algorithm that controls not only the delivery of therapy but also the magnitude of the delivered therapy. This system can be less intrusive to the patient's activities because system 100 adapts the stimulation to the patient's current needs, and thus reduces side effects experienced by the patient.
[0075] In some cases, as described herein, system 100 may deliver electrical stimulation at a lower amount than is necessary for patient 112 to prevent his or her symptoms from flaring up, based on upper and lower thresholds of a steady-state window. For example, patients receiving therapy from IMD 106 (which uses a steady-state window to control the delivery of electrical stimulation therapy) may experience less desirable outcomes in certain situations compared to when the patient receives continuous electrical stimulation therapy at the maximum therapeutic amount. To prevent these from occurring, system 100 may determine the value of at least one electrical stimulation parameter as defined by the steady-state window as described above. Furthermore, IMD 106 of system 100 may increase the value of this at least one electrical stimulation parameter by a larger bias than the determined amount defined by the steady-state window to further prevent patient 112 from flaring up symptoms. Thus, system 100 can avoid delivering electrical stimulation therapy with amounts that may be insufficient to prevent symptom flaring up.
[0076] Figure 1 The architecture of the illustrated system 100 is shown as an example. The techniques described in this disclosure can be applied to... Figure 1 The example system 100 and other types of systems not specifically described herein are implemented. Nothing in this disclosure should be construed as limiting the technology of this disclosure to... Figure 1 The example architecture is shown.
[0077] Figure 2 It is configured to deliver adaptive deep brain stimulation therapy. Figure 1 A block diagram of example IMD 106. Figure 2In the example shown, IMD 106 includes processing circuitry 210, memory 211, stimulus generator 202, sensing module 204, switching module 206, telemetry module 208, sensor 212, and power supply 220. Each of these modules may be or includes circuitry configured to perform the functions attributed to each respective module. For example, processing circuitry 210 may include one or more processor portions of processing circuitry, switching module 206 may include switching circuitry, sensing module 204 may include sensing circuitry, stimulus generator 202 may include stimulus generation circuitry, and telemetry module 208 may include telemetry circuitry. Switching module 204 may not be necessary for a configuration of multiple current sources and sinks, each directly connected to each electrode but connected or disconnected via corresponding switches. Memory 211 may include any volatile or non-volatile medium, such as random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically erasable programmable ROM (EEPROM), and flash memory. The memory 211 may store computer-readable instructions that, when executed by the processing circuitry 210, cause the IMD 106 to perform various functions. The memory 211 may be a storage device or other non-transitory medium.
[0078] exist Figure 2 In the example shown, memory 211 stores therapeutic procedures 214 and sensing electrode combinations, along with associated stimulation electrode combinations 218, in a separate memory or a separate region within memory 211. Each stored therapeutic procedure 214 defines a specific set of electrical stimulation parameters (e.g., a set of therapeutic parameters), such as stimulation electrode combinations, electrode polarity, current or voltage amplitude, pulse width, and pulse frequency. In some examples, individual therapeutic procedures may be stored as therapeutic groups, which define a set of therapeutic procedures that can be used to generate stimulation. Stimulation signals defined by the therapeutic procedures of a therapeutic group may be delivered together on an overlapping or non-overlapping (e.g., time-staggered) basis. Therapeutic procedures 214 may also store adaptive stimulation parameters that define adaptive stimulation, such as one or more thresholds of a steady-state window and / or one or more limits of a therapeutic window. For example, processing circuitry 210 may directly change and / or update any of these parameter values based on commands from programmer 104.
[0079] Sensing and stimulating electrode combinations 218 store sensing electrode combinations and associated stimulating electrode combinations. As described above, in some examples, sensing and stimulating electrode combinations may include the same subset of electrodes 116, 118, the housing of IMD 106 used as an electrode, or may include different subsets or combinations of such electrodes. Therefore, memory 211 may store multiple sensing electrode combinations, and for each sensing electrode combination, store information identifying the stimulating electrode combination associated with the corresponding sensing electrode combination. The association between sensing and stimulating electrode combinations may be determined automatically, for example, by processing circuitry 210. In some examples, corresponding sensing electrode combinations and stimulating electrode combinations may include some or all of the same electrodes. However, in other examples, some or all of the electrodes in the corresponding sensing electrode combination and stimulating electrode combination may be different. For example, a stimulating electrode combination may include more electrodes than the corresponding sensing electrode combination to increase the efficacy of the stimulation therapy. In some examples, as discussed above, stimulation can be delivered via a combination of stimulating electrodes to a tissue site that is different from the tissue site in the same region of the brain 120 (e.g., the thalamus) that is closest to the corresponding combination of sensing electrodes, in order to mitigate any irregular oscillations or other irregular brain activity within the tissue site associated with the combination of sensing electrodes.
[0080] Under the control of processing circuitry 210, stimulator 202 generates stimulation signals for delivery to patient 112 via a selected combination of electrodes 116, 118. Examples of electrical stimulation parameters believed to be effective in managing patient movement disorders in DBS include: 1. Pulse frequency, i.e. frequency: between approximately 40 Hz and approximately 500 Hz, such as between approximately 40 Hz and 185 Hz or such as approximately 140 Hz.
[0081] 2. In the case of a voltage control system, the voltage amplitude is between approximately 0.1 volts and approximately 50 volts, such as between approximately 2 volts and approximately 3 volts.
[0082] 3. In alternative current control systems, the current amplitude is between approximately 0.2 mA and approximately 100 mA, such as between approximately 1.3 mA and approximately 2.0 mA.
[0083] 4. Pulse width: Between approximately 10 microseconds and approximately 5000 microseconds, such as between approximately 100 microseconds and approximately 1000 microseconds, or between approximately 180 microseconds and approximately 450 microseconds.
[0084] Therefore, in some examples, the stimulator 202 generates an electrical stimulation signal based on the aforementioned electrical stimulation parameters and applies one or more of these parameters according to an upper and lower threshold of the treatment window, such that the applicable parameters are within the range specified by the window. Other ranges of therapeutic parameter values may also be useful and may depend on the target stimulation site within the patient 112. Although stimulation pulses are described, the stimulation signal may be of any form, such as a continuous-time signal (e.g., a sine wave).
[0085] Processing circuitry 210 may include fixed-function processing circuitry and / or programmable processing circuitry, and may include one or more of the following: a microprocessor, a controller, a digital signal processor (DSP), an application-specific integrated circuit (ASIC), a field-programmable gate array (FPGA), discrete logic circuitry, or any other processing circuitry configured to provide the functions attributed to processing circuitry 210, which may herein be embodied as firmware, hardware, software, or any combination thereof. Processing circuitry 210 may control stimulation generator 202 according to therapeutic program 214 stored in memory 211 to apply one or more specific stimulation parameter values specified by the program, such as voltage amplitude or current amplitude, pulse width, or pulse rate.
[0086] exist Figure 2 In the example shown, the set of electrodes 116 includes electrodes 116A, 116B, 116C, and 116D, and the set of electrodes 118 includes electrodes 118A, 118B, 118C, and 118D. Processing circuitry 210 also controls switching module 206 to apply the stimulation signal generated by stimulation generator 202 to a selected combination of electrodes 116, 118. Specifically, switching module 204 can couple the stimulation signal to a selected conductor within lead 114, which then delivers the stimulation signal across the selected electrodes 116, 118. Switching module 206 can be a switch array, switch matrix, multiplexer, or any other type of switching module configured to selectively couple stimulation energy to the selected electrodes 116, 118 and selectively sense brain bioelectrical signals using the selected electrodes 116, 118. Thus, stimulation generator 202 is coupled to electrodes 116, 118 via switching module 206 and conductors within lead 114. However, in some examples, IMD 106 does not include switch module 206.
[0087] Stimulation generator 202 can be a single-channel or multi-channel stimulation generator. Specifically, stimulation generator 202 may be able to deliver a single stimulation pulse, multiple stimulation pulses, or a continuous signal at a given time via a single electrode combination, or deliver multiple stimulation pulses at a given time via multiple electrode combinations. However, in some examples, stimulation generator 202 and switching module 206 may be configured to deliver multiple channels on a time-interleaved basis (e.g., pulses from one channel are at least partially alternated with at least some pulses from another channel). For example, switching module 206 may be used to time-divide the output of stimulation generator 202 across different electrode combinations at different times to deliver a program or channel of multiple stimulation energies to patient 112. Alternatively, stimulation generator 202 may include multiple voltage or current sources and voltage or current sinks coupled to corresponding electrodes to drive electrodes serving as cathodes or anodes. In this example, IMD 106 may not require the functionality of switching module 206 to time-interleave multiplexing stimulations via different electrodes.
[0088] The electrodes 116, 118 on the corresponding leads 114 can be constructed using a variety of different designs. For example, one or two leads in the leads 114 may include two or more electrodes at each longitudinal location along the length of the lead, such as multiple electrodes at different peripheral locations around the periphery of the lead at each of locations A, B, C, and D. In one example, the electrodes may be electrically coupled to the switch module 206 via the corresponding leads, which are straightened or coiled within the housing of the leads and extend to a connector at the proximal end of the leads. In another example, each electrode in the leads may be an electrode deposited on a thin film. The thin film may include conductive traces for each electrode that extend along the length of the film to the proximal end connector. The thin film may then be wound (e.g., helically wound) around an internal component to form the leads 114. These and other configurations can be used to form leads with complex electrode geometries.
[0089] Despite Figure 2 The sensing module 204 is incorporated into a common housing along with the stimulus generator 202 and processing circuitry 210. However, in other instances, the sensing module 204 may be housed in a separate housing from the IMD 106 and may communicate with the processing circuitry 210 via wired or wireless communication technologies. Example brain bioelectrical signals include, but are not limited to, signals generated by local field potentials (LFPs) in one or more regions of the brain 28. EEG and ECoG signals are further examples of electrical signals that can be measured within the brain 120 or by electrodes placed at other locations relative to the brain 120.
[0090] Sensor 212 may include one or more sensing elements that sense values of corresponding patient parameters. For example, sensor 212 may include one or more accelerometers, optical sensors, chemical sensors, temperature sensors, pressure sensors, or any other type of sensor. Sensor 212 may output patient parameter values that can be used as feedback to control therapy delivery. IMD 106 may include additional sensors within the housing of IMD 106 and / or coupled via one of leads 114 or other leads. Furthermore, IMD 106 may wirelessly receive sensor signals from remote sensors, for example, via telemetry module 208. In some examples, one or more of these remote sensors may be located outside the patient's body (e.g., carried on an external surface of the skin, attached to clothing, or otherwise positioned outside the patient's body). Processing circuitry 210 may identify and / or store patient events based on signals from sensor 212.
[0091] Telemetry module 208, under the control of processing circuitry 210, supports wireless communication between IMD 106 and external programmer 104 or another computing device. As an update to the program, processing circuitry 210 of IMD 106 can receive values of various stimulation parameters (such as magnitudes and electrode combinations) from programmer 104 via telemetry module 208. Updates to the therapy program can be stored in the therapy program 214 portion of memory 211. Telemetry module 208 in IMD 106, as well as telemetry modules in other devices and systems described herein (such as programmer 104), can communicate via radio frequency (RF) communication technology. Furthermore, telemetry module 208 can communicate with external medical device programmer 104 via proximal sensor interaction between IMD 106 and programmer 104. Therefore, telemetry module 208 can continuously, periodically, or upon request from IMD 106 or programmer 104, transmit information to external programmer 104.
[0092] Power source 220 delivers operating power to the various components of IMD 106. Power source 220 may include a small rechargeable or non-rechargeable battery and power generation circuitry to generate operating power. Recharging is achieved via proximal inductive interaction between an external charger and an inductive charging coil within IMD 220. In some examples, the power requirement may be small enough to allow IMD 220 to utilize patient movement and implement kinetic energy harvesting to trickle charge a rechargeable battery. In other examples, conventional batteries may be used for a limited time.
[0093] According to the technology disclosed herein, the processing circuitry 210 of the IMD 106 delivers electrical stimulation therapy to the patient 112 via electrodes 116, 118 inserted along leads 114 (and optionally switch module 206). The aDBS therapy is defined by one or more therapy programs 214, which have one or more parameters (and may specify adaptive modes and corresponding thresholds) stored in memory 211. For example, one or more parameters may include current amplitude (for a current control system) or voltage amplitude (for a voltage control system), pulse frequency or frequency, and pulse width or the number of pulses per cycle. A set of one or more parameter values defines a parameter set that defines each therapy program. In an example of delivering electrical stimulation based on a “burst” of pulses or a series of electrical pulses defined by “on time” and “off time”, one or more parameters may also define one or more of the number of pulses per burst, on time, and off time. In one example, a treatment window defines an upper and lower limit for the voltage amplitude of the electrical stimulation therapy. In another example, a treatment window defines an upper and lower limit for the current amplitude of the electrical stimulation therapy. Specifically, parameters of electrical stimulation therapy, such as voltage or current amplitude, are limited by a treatment window with upper and lower limits, allowing the voltage or current amplitude to be adjusted as long as it remains greater than or equal to the lower limit and less than or equal to the upper limit. Note that a single limit may be used in some examples.
[0094] In one example, processing circuitry 210 monitors the behavior of signals from patient 112 within a steady-state window, which is related to one or more symptoms of the patient 112's disease, via electrodes 116, 118 of IMD 106. Processing circuitry 210 delivers aDBS to patient 112 via electrodes 116, 118 and can adjust one or more parameters defining the electrical stimulation within a parameter range defined by a lower and upper threshold of the treatment window, based on the activity of the sensed signals within the steady-state window.
[0095] In one example, the signal is a bioelectrical signal (e.g., LFP signal) within the beta band of the brain 120 of patient 112. The signal within the beta band of patient 112 may be associated with one or more symptoms of Parkinson's disease in patient 112. Generally, the bioelectrical signal within the beta band of patient 112 may be roughly proportional to the severity of patient 112's symptoms. For example, as tremor induced by Parkinson's disease increases, one or more electrodes of electrodes 116, 118 detect an increase in the magnitude of the bioelectrical signal within the beta band of patient 112.
[0096] Similarly, as the tremor induced by Parkinson's disease decreases, the magnitude of the bioelectrical signal in the β band of patient 112 detected by processing circuit 210 via one or more of electrodes 116, 118 also decreases. In another example, the signal is a bioelectrical signal in the γ band of patient 112's brain 120. The signal in the γ band of patient 112 may also be associated with one or more side effects of electrostimulation therapy. However, unlike the bioelectrical signal in the β band, in general, the bioelectrical signal in the γ band of patient 112 may be roughly inversely proportional to the severity of the side effects of electrostimulation therapy. For example, as the side effects caused by electrostimulation therapy increase, the magnitude of the signal in the γ band of patient 112 detected by processing circuit 210 via one or more of electrodes 116, 118 decreases. Similarly, as the side effects caused by electrostimulation therapy decrease, the magnitude of the signal in the γ band of patient 112 detected by processing circuit 210 via one or more of electrodes 116, 118 increases.
[0097] In response to the detection that a patient's signal (e.g., a sensed bioelectrical signal) has deviated from a steady-state window, processing circuitry 210 dynamically adjusts the magnitude of one or more parameters of the electrical stimulation therapy (such as, for example, pulse current amplitude or pulse voltage amplitude) to drive the patient's signal back into the steady-state window. For example, where the signal is a bioelectrical signal within the β band of the brain 120 of patient 112, processing circuitry 210 monitors the β magnitude of patient 112 via one or more electrodes 116, 118. When the β magnitude of patient 112 is detected to exceed the upper limit of the steady-state window, processing circuitry 210 increases the magnitude of the electrical stimulation delivered via electrodes 116, 118 at a maximum ramp rate, for example automatically or as determined by a clinician, until the magnitude of the bioelectrical signal within the β band falls back into the steady-state window, or until the magnitude of the electrical stimulation reaches the level set by system 100 (…). Figure 1 The upper limit of the treatment window is determined by the system 100. Similarly, when the beta value of patient 112 is detected to have dropped below the lower limit of the steady-state window, the processing circuit 210 reduces the stimulation value at a maximum ramp rate determined by the system 100 until the beta value rises back into the steady-state window, or until the electrical stimulation value reaches the lower limit of the treatment window determined by the system 100. When the beta value is detected to be currently within the threshold of the steady-state window or has returned to the threshold of the steady-state window, the processing circuit 210 keeps the electrical stimulation value constant. In other examples, the processing 210 may automatically determine the ramp rate when adjusting the stimulation parameters to bring the brain signal back into the target range. The ramp rate may be selected based on previous data indicating general patient comfort or the comfort or preference of a specific patient.
[0098] In some examples, processing circuitry 210 measures the signal continuously in real time. In other examples, processing circuitry 210 samples one or more bioelectrical signals periodically according to a predetermined frequency or after a predetermined amount of time. In some examples, processing circuitry 210 samples the signal periodically at a frequency of approximately 150 Hz.
[0099] Furthermore, processing circuitry 210 delivers electrical stimulation therapy constrained by upper and lower limits of a treatment window. In some examples, the values defining the treatment window are stored in memory 211 of IMD 106. For example, in response to detecting that a brain signal has deviated from the steady-state window, processing circuitry 210 of IMD 106 may adjust one or more parameters of the electrical stimulation therapy to provide responsive treatment to patient 112. For example, in response to detecting that a signal has exceeded the upper threshold of the steady-state window and before delivering electrical stimulation therapy, processing circuitry 210 increases the amplitude of the stimulation (e.g., but not above the upper limit) to bring the signal back below the upper threshold. For example, in a voltage control system where the clinician has set the upper limit of the treatment window to 3 volts, processing circuitry 210 may increase the voltage amplitude to a value no greater than 3 volts to attempt to reduce the brain signal below the upper threshold.
[0100] In another example, in response to detecting that the signal has dropped below the lower threshold of the steady-state window and before delivering electrical stimulation therapy, processing circuit 210 reduces, for example, the voltage amplitude, but not below the lower threshold. For example, in the voltage control system described above where the clinician has set the lower limit of the treatment window to 1.2 volts, processing circuit 210 may reduce the voltage amplitude to at least 1.2 volts in an attempt to raise the brain signal back above the lower threshold and into the steady-state window. Thus, processing circuit 210 of IMD 106 can deliver aDBS to patient 112, wherein one or more parameters defining aDBS are within the treatment window defined by the lower and upper limits of the parameters.
[0101] In the aforementioned example, the limits of the treatment window are inclusive (i.e., the upper and lower limits are valid values for the one or more parameters). However, in other examples, the limits of the treatment window are non-inclusive (i.e., the upper and lower limits are not valid values for the one or more parameters). In such an example of a non-inclusive treatment window, the processing circuit 210 instead sets the adjustment to the one or more parameters to the second highest valid value (if the adjustment potentially exceeds the upper limit) or the second lowest valid value (if the adjustment potentially exceeds the lower limit).
[0102] In another example, the value defining the treatment window is stored in the memory 311 of the external programmer 104. In this example, in response to detecting that the signal has deviated from the steady-state window, the processing circuitry 210 of the IMD 106 sends data representing the measured value of the signal to the external programmer 104 via the telemetry module 208. In one example, in response to detecting that the signal has exceeded the upper threshold of the steady-state window, the processing circuitry 210 of the IMD 106 sends data representing the measured value of the signal to the external programmer 104 via the telemetry module 208. The external programmer 104 can determine to adjust parameter values to reduce the signal below the upper threshold, as long as the parameter values remain within one or more limits of that parameter.
[0103] In another example, processing circuitry 210 receives instructions from external programmer 104 via telemetry module 208 to adjust one or more limits of the treatment window. For example, such instructions may be in response to patient feedback regarding the efficacy of the electrical stimulation therapy, or to one or more sensors that have detected signals from the patient. Such signals from sensors may include bioelectrical signals (such as signals in the beta or gamma band of the patient 112's brain 120) or physiological parameters and measurements (such as signals indicating one or more of the patient's activity level, posture, and respiratory function). Furthermore, such signals from sensors may indicate that one or more symptoms of the patient 112 have not been alleviated (such as tremor or rigidity) or that side effects caused by the electrical stimulation therapy (such as paresthesia) are present. In response to these instructions, processing circuitry 210 may adjust one or more thresholds of the steady-state window. For example, processing circuitry 210 may adjust the magnitude of an upper threshold, a lower threshold, or shift the overall positioning of the steady-state window such that the thresholds for adjusting one or more parameters of the electrical stimulation defined by the steady-state window adjust automatically. Then, the processing circuit 210 delivers the adjusted electrical stimulation to the patient 112 via electrodes 116 and 118.
[0104] Figure 3 yes Figure 1 A block diagram of an external programmer 104. Although programmer 104 is generally described as a handheld device, it can be a larger portable device or a more fixed device. In some examples, programmer 104 may be referred to as a tablet computing device. Furthermore, in other examples, programmer 104 may be included as part of an external charging device or include the functionality of an external charging device. Figure 3As illustrated, programmer 104 may include processing circuitry 310, memory 311, user interface 302, telemetry module 308, and power supply 320. Throughout this disclosure, memory 311 may store instructions that, when executed by processing circuitry 310, enable processing circuitry 310 and external programmer 104 to provide functionality attributable to external programmer 104. Each of these components or modules may include circuitry configured to perform some or all of the functionality described herein. For example, processing circuitry 310 may include processing circuitry configured to perform the processes discussed relative to processing circuitry 310.
[0105] Generally, programmer 104 includes any suitable hardware arrangement, alone or in combination with software and / or firmware, to execute techniques belonging to programmer 104 and its processing circuitry 310, user interface 302, and telemetry module 308. In various examples, programmer 104 may include one or more processors, which may include fixed-function processing circuitry and / or programmable processing circuitry, such as those formed by, for example, one or more microprocessors, DSPs, ASICs, FPGAs, or any other equivalent integrated or discrete logic circuitry, and any combination of such components. In various examples, programmer 104 may also include memory 311 (such as RAM, ROM, PROM, EPROM, EEPROM, flash memory, hard disk, CD-ROM) containing executable instructions for causing one or more processors to perform actions belonging to them. Furthermore, although processing circuitry 310 and telemetry module 308 are described as separate modules, in some examples, processing circuitry 310 and telemetry module 308 may be functionally integrated with each other. However, in some examples, the processing circuit 310 and the telemetry module 308 correspond to separate hardware units, such as ASICs, DSPs, FPGAs, or other hardware units.
[0106] Throughout this disclosure, memory 311 (e.g., a storage device) may store instructions that, when executed by processing circuitry 310, enable processing circuitry 310 and programmer 104 to provide functionality attributable to programmer 104. For example, memory 311 may include instructions for: enabling processing circuitry 310 to retrieve a set of parameters from memory, selecting one or more parameters based on sensed signals for electrical or adaptive stimulation, or receiving user input and sending corresponding commands to IMD 104; or instructions for any other functionality. Furthermore, memory 311 may include multiple programs, each including a set of parameters defining a stimulation therapy.
[0107] User interface 302 may include buttons or a keypad, lights, a speaker for voice commands, and a display (such as a liquid crystal (LCD), light-emitting diode (LED), or organic light-emitting diode (OLED)). In some examples, the display may be a touchscreen. User interface 302 may be configured to display any information related to the delivery of stimulation therapy, identified patient behavior, sensed patient parameter values, automatically selected parameters, prompts for the user regarding stimulation parameters or adaptive stimulation parameters, patient behavior criteria, or any other such information. User interface 302 may also receive user input. User input may be in the form of, for example, pressing a button on a keypad or selecting an icon from a touchscreen. User input may indicate that a patient event has occurred, and in some examples, may indicate the type of patient event (e.g., a symptom occurred, a side effect occurred, or any other type of patient event). In some examples, processing circuitry 310 may timestamp the patient event for correlation with sensed signals later retrieved from IMD 106. In some examples, processing circuitry 310 may send indications of patient events to IMD 106 to associate patient events and store sensed signals, and / or immediately request sensed signals from IMD 106 to associate with patient events and store them in memory 311 for further processing. User interface 302 may refer to hardware configured to present information to a user and / or receive input from a user. In some examples, processing circuitry 310 directly controls this hardware. In other examples, processing circuitry 310 may communicate with driver hardware that controls the hardware controlling user interface 302. In some examples, user interface 302 may include display configurations and / or interactive display configurations as described herein.
[0108] Telemetry module 308 can support wireless communication between IMD 106 and programmer 104 under the control of processing circuitry 310. Telemetry module 308 can also be configured to communicate with another computing device via wireless communication technology or directly with another computing device via a wired connection. In some examples, telemetry module 308 provides wireless communication via RF or near-side sensing media. In some examples, telemetry module 308 includes an antenna, which can take various forms, such as an internal antenna or an external antenna. In some examples, telemetry module 308 can support communication with an intermediary device between programmer 104 and IMD 106, or other external devices.
[0109] Examples of local wireless communication technologies that can be used to facilitate communication between programmer 104 and IMD 106 include RF communication according to 802.11 or Bluetooth specification sets or other standards, inductive telemetry, or proprietary telemetry protocols. In this way, other external devices can be able to communicate with programmer 104 without establishing a secure wireless connection. As described herein, telemetry module 308 can be configured to send spatial electrode movement patterns or other stimulation parameter values to IMD 106 for the delivery of stimulation therapy.
[0110] According to the technology disclosed herein, in some examples, the processing circuitry 310 of the external programmer 104 defines parameters of a steady-state treatment window stored in memory 311 for delivering aDBS to the patient 112. In one example, the processor 311 of the external programmer 104 issues a command to the IMD 106 via telemetry module 308, causing the IMD 106 to deliver electrical stimulation therapy via electrodes 116, 118 and via lead 114.
[0111] The following examples illustrate various user interfaces and techniques for sensing physiological signals (such as brain signals), programming adaptive stimulation therapies, and managing electrical stimulation as described herein. Programmer 104 or another external computing device can output the user interfaces and screens described herein. Example user interface screens may be presented individually or selected in any order, or programmer 106 may present each screen sequentially as part of one or more automated programming processes to assist the user in completing the programming process for setting or adjusting adaptive stimulation therapies. The user may be prompted for input at various times to select parameter values or confirm automatically selected parameter values. In some examples, programmer 106 may automate each step and present the fully automated and selected parameters to the user at the end of the process. The user can use each corresponding screen of the user interface as needed to confirm parameter values or view one or more parameter values to customize the stimulation therapy, which may include adaptive stimulation therapies (such as aDBS).
[0112] Figure 4 This is a conceptual diagram illustrating a sample main screen 402 used for navigation within a sample user interface 400. The user interface 400 may include several different screens because the user can navigate to different functions to view sensed information, view stored data, or determine or adjust various stimulus parameter values. Figure 4As shown in the example, the main screen 402 includes information associated with patient 112, such as patient-specific information 406, such as name, patient ID, date of birth, and patient diagnosis. Other information may include device-specific information, such as model, implantation date, battery level, and estimated remaining battery life. Information such as system impedance status and event summary may also be provided on the main screen 402. Screen 402 may also include a stimulation toggle switch 404, which toggles between stimulating on or off when selected. The stimulation toggle switch 404 may be provided on some, most, or all of the different screens within the user interface 400 to allow the user to turn stimulation on or off at any time. The alarm button 410 indicates “No Alarm” because there is no alarm to display. However, if an alarm exists for the user, the alarm button 410 may indicate the presence or number of alarms, and the alarm button 410 may be selectable to allow the user interface 400 to display a list of alarms for the user. Example alarms may include aspects of the system that are out of specification or one or more aspects related to the stimulation that still need to be completed so that therapy can be delivered to patient 112.
[0113] Figure 4 The main screen 402 may also include a menu 408 containing several selectable buttons that allow the user to navigate to other screens and functionalities supported by the user interface 400. These selectable buttons include "Settings," "Stimulation," "Impedance," "MRI Eligibility," "Alternate," "Event," and "End Session." The programmer 104 can switch to the appropriate screen in response to a user selection of the corresponding selectable button. Selection of each item in menu 408 causes the user interface 400 to display one or more screens associated with that section of the user interface. Once within one screen of the user interface 400, the user interface 400 can continue guiding the user through the remainder of the therapy setup from that point. However, the user can jump between different screens as needed by selecting different functions from various menus within each screen of the user interface 400.
[0114] like Figure 4 As shown in the example, in response to user selection, the Settings button takes the user to a screen associated with selecting the electrode combination used for sensing and / or stimulation and / or the frequency used for sensing. In response to user selection, the Stimulation button takes the user to a screen associated with managing the patient's electrical stimulation therapy, such as selecting an adaptive stimulation mode, selecting a threshold for the adaptive mode, selecting parameters to define the stimulation, limits for the stimulation parameters, or any other parameters related to the stimulation therapy. In response to user selection, the Impedance button takes the user to a screen associated with viewing the impedance of one or more electrode combinations and / or leads, as well as impedance testing of any electrical pathways.
[0115] The MRI Eligibility button leads the user to a screen associated with MRI eligibility for examining any implanted device (e.g., IMD 106) and / or placing the implanted device in a pattern that qualifies for MRI eligibility. The Replace button causes the user interface 400 to replace a screen associated with when the IMD 106 should be replaced (e.g., the remaining operational life of a non-rechargeable primary battery). The Event button allows the user to navigate to various screens displaying events (e.g., patient events) and data associated with sensing and delivering electrical stimulation. The End Session button allows the user to terminate a management session via the user interface 400. In addition to this menu, the user interface 400 may also include a stimulation toggle switch that allows the user to request stimulation to be turned on or off. These different navigation categories in menu 408 are merely examples, and in other examples, the functionality within each category may be divided into additional categories or combined into fewer categories.
[0116] User interface 400 enables the system to automatically determine various parameters related to adaptive stimulation therapy. In some examples, system 100 may use user input provided via user interface 400 to initiate automated processes related to parameter selection, provide recommended parameters for user confirmation, present sensed data, or otherwise enable the user to manage the stimulation therapy. Thus, user interface 400, provided by programmer 106 or another external device, can provide automated sensing of bioelectrical signals, selection of one or more thresholds for adaptive modes, parameter thresholds for stimulation, and / or any other selectable parameters related to closed-loop adaptive stimulation therapy. In some examples, the automated process can perform all of these processes and display recommended parameters and modes on a single final screen for user confirmation. In some examples, user interface 400 may present a screen after each parameter selection step, displaying recommended parameter values or recommended ranges for the user to confirm or select before moving to the next step. In other examples, system 100 may present automated recommendations for selectable parameters at each step via user interface 400 as the user moves through different screens of user interface 400. In this way, the user has access to available system-recommended parameter values to avoid manual selection. In any case, the user interface 400 may provide one or more opportunities to the automated process for the user to view, confirm, and / or change automation parameter values or other options. In some examples, as time progresses during the treatment process, the user may return to any of these screens during follow-up visits to the patient.
[0117] As described herein, system 100 enables the automated selection of one or more parameters associated with adaptive stimulation therapy, which utilizes one or more feedback variables for closed-loop therapy. An example type of adaptive therapy is aDBS, but other types of therapy can similarly achieve automatic adjustment based on one or more sensed signals from the patient. In one example, system 100 includes memory and processing circuitry, such as processing circuitry 210, processing circuitry 310, or processing circuitry from other devices, or any combination thereof. Processing circuitry 310 of programmer 106 will generally be described herein as an example, but other circuitry, devices, or combinations thereof may perform similar functions. Processing circuitry 310 may be coupled to memory and configured to control sensing circuitry (e.g., sensing circuitry of sensing module 204) to sense multiple bioelectrical signals from the patient's brain via multiple different electrode combinations. Processing circuitry 310 may also receive information representing the multiple bioelectrical signals (e.g., data representing sensed voltages between electrodes of the electrode combination over time) and determine spectral power information based on the information representing the multiple bioelectrical signals. Processing circuitry 310 or another processor may perform a Fast Fourier Transform (FFT) to transform the voltage information from the time domain to the frequency domain. Based on this spectral power information, processing circuitry 310 may determine characteristics, such as power characteristics, that represent the sensed signal at a specific frequency or frequency band. These characteristics can normalize the sensed signal into an indication of the current physiological condition.
[0118] The memory 311 may include threshold determination instructions. These threshold determination instructions determine how the processing circuit 310 determines the value or range of one or more thresholds based on the sensed signals. The processing circuit 310 may be configured to receive event information representing sensed brain bioelectrical signals corresponding to one or more patient events identified during the delivery of adaptive deep brain stimulation therapy to a patient. In this way, the event information may include the sensed brain signals and / or characteristics representing the brain signals, such as power characteristics. The processing circuit 310 may then determine a range of values defining at least one threshold for the adaptive deep brain stimulation therapy based on the event information and the threshold determination instructions. This range of values may be determined to reduce the occurrence of one or more patient events during the delivery of subsequent adaptive deep brain stimulation therapy. For example, if the event information indicates that symptoms have occurred even though the sensed signal does not exceed a threshold, the processing circuit 310 may determine a range of values that may be more appropriate for adjusting the threshold to a new value where symptoms will no longer occur. The range of values may be an actual range or a recommended minimum or maximum threshold value, wherein the selected value for determining the threshold should be equal to or higher than the minimum value or equal to or lower than the maximum recommended threshold value.
[0119] Using these adaptive stimulation parameters (such as thresholds within a range of values), processing circuitry 310 can control deep brain stimulation therapy via an electrode combination based on one or more thresholds and subsequently sensed bioelectrical signals. Processing circuitry 310 can present the selected parameters to a user via user interface 400 for confirmation before initiating therapy using these parameters. Processing circuitry 310 can also control the selected parameters to be sent to IMD 104 for use in stimulation therapy as part of controlling the stimulation therapy.
[0120] In some examples, a patient event may include at least one of the occurrence of a symptom or a side effect. A symptom or event may include patient sensation, patient movement, falls, slurred speech, motor impairment, or any other aspect that may be associated with the patient's condition and / or inappropriate treatment. Therefore, patient events are often likely associated with ineffective treatment. However, in some examples, a patient event may be an indication of positive treatment that processing circuitry 310 can, for example, use to reinforce an appropriate threshold.
[0121] The sensed brain bioelectrical signals may be local field potential (LFP) signals, and information representing the sensed brain signals may include characteristic values indicating the power of the LFP signals. In some examples, processing circuitry 310 may be configured to calculate the characteristic values by at least the following operations: determining the spectral power value of the LFP signal in each of a plurality of time periods; and summing the spectral power from each of the plurality of time periods to calculate a total power corresponding to the patient event, which is the characteristic value. In this way, processing circuitry 310 can establish multiple time “bins” within the time period of the patient event and calculate the characteristic value of the signal in each bin. This segmentation allows processing circuitry 310 to compare different patient events with each other and identify appropriate thresholds for subsequent adaptive therapy.
[0122] In some examples, processing circuitry 310 can automatically determine a value within a range of at least one threshold value based on event information and threshold determination instructions. For example, processing circuitry 310 can calculate an appropriate value for a threshold that falls within that range. This appropriate value may be the same as the minimum or maximum threshold of the range, or it may be set as a percentage of the minimum or maximum threshold, or it may be at a predetermined offset from the minimum or maximum threshold. In this way, processing circuitry 310 can be configured to identify potentially valid thresholds based on a range of values.
[0123] In other examples, processing circuitry 310 may prompt the user to select a threshold value within a range. For example, processing circuitry 310 may control the display device of programmer 104 to present a range of values via a user interface (e.g., user interface 302 or 400). Processing circuitry 310 may then receive user input via the user interface to select a value within that range. For example, the selection of a value may be a user-inputted numerical value, the user moving a slider to a numerical position within the range, or some other user input specifying a desired value for one or more thresholds. Processing circuitry 310 may then control IMD 106 to deliver subsequent adaptive deep brain stimulation therapy based on the value of at least one threshold. In this example, one or more thresholds include upper and lower thresholds (e.g., a steady-state window) that define the adaptive deep brain stimulation therapy and subsequent adaptive deep brain stimulation therapy. In some examples, user input may specify each threshold independently. In other examples, the user may determine the thresholds together to maintain the desired range of the window while simultaneously changing the lower and upper threshold values together. In some examples, processing circuitry 310 may automatically determine one or more limits of stimulation parameters (e.g., amplitude and / or treatment window) based on event information. For example, based on the sensed signal and / or amplitude used during adaptive stimulation therapy, processing circuitry 310 may increase or decrease one or more of these limits to reduce the occurrence of another patient event. In some examples, processing circuitry 310 may present a user interface to display input fields, whereby a user may adjust one or more limits based on changes in thresholds, automatically generated limits or limits range suggestions, and / or stimulation parameter data presented during the patient event. Processing circuitry 310 may then receive user input specifying the updated limits for the stimulation parameters.
[0124] Processing circuitry 310 or another device may be configured to control stimulation by directly directing changes to the stimulation based on sensed signals. In some examples, processing circuitry 310 may control stimulation by controlling telemetry circuitry to send instructions (such as frequency and one or more thresholds) to IMD 104 to control the delivery of deep brain electrical stimulation.
[0125] System 100 can determine various parameters automatically or using user input. These parameters may include the combination of sensing electrodes with leads and the frequency (such as in the frequency domain) to be used to monitor the sensed signal. The combination of sensing electrodes and the frequency used for sensing can be determined based on initial LFP data obtained from the patient.
[0126] Figure 5 This is a conceptual diagram illustrating an example screen for selecting an adaptive therapy mode (e.g., aDBS mode) from two or more different adaptive modes. Figure 5As shown in the example, the user interface 400 may include a screen 502 indicating an automated or manual system selection for a dual-threshold mode 506, a single-threshold mode 508, or a single-threshold inverse mode 510. Dual-threshold mode 506 is shown as selected. Dual-threshold mode 506 enables the system to adjust the stimulus amplitude based on an upper and lower threshold of the LFP signal. Single-threshold mode 508 enables the system to increase the stimulus when the LFP signal is above a threshold, and single-threshold inverse mode 510 enables the system to decrease the stimulus when the LFP signal is below a threshold.
[0127] Processing circuitry 310 can automatically determine which adaptive mode to use based on sensed bioelectrical signals and patient events. For example, processing circuitry 310 can identify whether the current adaptive mode is adequately treating the patient. Based on patient events and signals sensed during these events, processing circuitry 310 can select different adaptive modes. This could be due to changes in the patient's disease progression or changes in the frequency band most effective in treating the patient's symptoms. For example, if patient events (such as symptoms) still occur under large stimulus amplitudes based on β signals, processing circuitry 310 can determine that alternatively, for example, a single-threshold inverse mode 510 can be used to track γ signals. In some examples, processing circuitry 310 can suggest a mode to select and request user input to confirm the suggestion. In other examples, the user can select a desired mode, and processing circuitry 310 can receive user input selecting that mode via screen 502.
[0128] Figure 6 This is a conceptual diagram of an example screen 600 illustrating the selection of one or more thresholds defining an aDBS therapy. Screen 600 may present a user interface 400 to select an initial threshold and / or modify the threshold during therapy. Figure 6 As shown in the example, a representation of the lead wire and the electrodes carried thereon is displayed on screen 600. Cathode and anode electrodes are also indicated to show the selected electrode configuration as part of lead wire view 604. A menu indicates that lead wire view 604 is currently displayed, but alternatively, annotations for electrode configuration 602 may be shown. To the right of lead wire view 604, LFP graph 606 and stimulation parameter graph 608 are displayed. A capture button allows the user to request the capture of the LFP at the current amplitude. At the far right of screen 600 is parameter view 614, which includes inputs selectable by the user to increase (button 618) and decrease (button 620) the stimulation parameters, which are... Figure 6 The example shows the current amplitude. Button 616 jumps to the set upper limit of amplitude. Button 622 jumps to the lower limit of amplitude (when set). The parameter button (not shown) allows the user to select the desired parameter to be adjusted, such as amplitude, pulse width, or frequency. Figure 6On this screen, the user can set the limit of parameter values corresponding to the respective thresholds of brain signals (such as LFP) by sliding or moving the upper threshold 634 and the lower threshold 636. The passive sensing button 640 allows the programmer 104 to save LFP values used only for sensing and not for adaptive stimulation. The user can move between different screens of the user interface 400 via the previous page button 512 and the next page button 514.
[0129] Using the screen 600 of the user interface 400, the user can capture thresholds for LFP corresponding to the respective stimulus parameter values, or otherwise set initial thresholds using an upper threshold 634 and / or a lower threshold 636. In this way, the system can use the stimulus as an actuator to determine the LFP classification thresholds. In one example, each threshold can be set based on measuring LFP for up to 25 seconds at a specific amplitude level defined by the patient's tolerance and symptom relief. Other sensing durations can be used in other examples.
[0130] Typically, to set upper and lower thresholds for brain signal monitoring, the patient has discontinued medication; that is, the upper and lower thresholds are set when the patient is not taking the medication chosen to alleviate these symptoms. A patient can be considered not taking medication if: for extended-release dopamine agonists, the patient has not taken the medication for at least approximately 72 hours prior to the time limit set; for conventional dopamine agonists and controlled-release CD / LDs, the patient has not taken the medication for at least approximately 24 hours; and for conventional CD / LDs, entacapone, rasagiline, selegiline, and amantadine, the patient has not taken the medication for at least approximately 12 hours. If the stimulation only inhibits brain signals (e.g., LFP signals), the system can measure these brain signals for individual values of the stimulation parameters without external input. Once the upper and lower thresholds are established, the system can identify when the drug's effect wears off as the brain signal crosses either the lower or upper threshold. In response to identifying a brain signal crossing a threshold, the system can activate electrical stimulation to restore the brain signal amplitude back to between the lower and upper thresholds. Thresholds can be set for certain brain signals (such as signals in the beta band) when the patient stops taking the medication. In some examples, such as when evaluating signals in the gamma band, thresholds can be set when the patient is taking the medication. In other examples, thresholds can be set for patients who are taking the medication.
[0131] When the patient is not taking any medication, LFP activity above a threshold (such as greater than or equal to 1.2 uVp) may be present. During this process, the user will identify the lowest current amplitude at which symptoms are controlled, which will be correlated with the upper threshold of the LFP signal. The user can select and drag slider 626 to increase or decrease the amplitude of the stimulus. This minimum amplitude will also be set as the lower limit of the stimulus parameters.
[0132] like Figure 6 As shown, screen 600 indicates that an upper limit threshold 634 has been set and is color-coordinated with the lower limit of the current amplitude (e.g., shown as the same color). A lower limit threshold 636 has been set and is color-coordinated with the upper limit of the current amplitude (e.g., shown as the same color, but different from the upper / lower limit). Apart from color, the upper and lower limits 634 have similar directional arrows, while the lower and upper limits 636 have similar directional arrows. In this way, the system can automatically adjust the current amplitude between the lower and upper limits to maintain the LFP signal between the lower and upper thresholds.
[0133] As illustrated herein, increasing the current amplitude (or other stimulation parameters that increase stimulation intensity) reduces the amplitude of the LFP signal at the selected frequency. Conversely, decreasing the current amplitude (or other stimulation parameters that decrease stimulation intensity) increases the amplitude of the LFP signal at the selected frequency. An LFP below the lower threshold may indicate that the patient is receiving excessive stimulation and has motor dysfunction, while an LFP above the upper threshold may indicate that the patient's symptoms are not effectively controlled. In some examples, the average power of the selected frequency over 30 seconds is captured as both the upper and lower thresholds. In some examples, the processing circuit 310 may employ error checking on the upper and lower thresholds. For example, if the capture would result in the upper threshold being lower than the lower threshold, the processing circuit 310 may refuse to capture the threshold. Additionally or alternatively, the processing circuit may perform statistical threshold checks to ensure that these thresholds are sufficiently separated from each other.
[0134] like Figure 6 As shown, this system can capture LFP during stimulus delivery. This is possible because the stimulating electrodes are different from the sensing electrodes. One benefit of this ability to capture LFP simultaneously with stimulus delivery is that LFP data can be identified when the patient arrives home, allowing the system to monitor the LFP threshold. As described herein, patient events can be tracked over time, and the sensed signals can be used to determine any changes in the threshold over time.
[0135] Figure 7 This is a flowchart illustrating an example technique for selecting an adaptive therapy mode for aDBS. Figure 7 The process can describe the manual determination of the initial threshold. However, this process can be repeated during therapy to update the appropriate threshold or confirm the system-recommended value or range. Figure 7In the example, processing circuit 310 receives user input (702) requesting the setting of a threshold for adaptive DBS. Then, processing circuit 310 captures an upper threshold for the LFP brain signal at the lower limit of the stimulus amplitude that alleviates the patient's symptoms (704). Processing circuit 310 then increases the stimulus amplitude based on the user input (706). Processing circuit 310 captures a lower threshold for the LFP brain signal at an upper limit slightly below the upper limit of the stimulus amplitude that would cause side effects in the patient (708). Processing circuit 310 then stores the threshold and limits of the adaptive DBS (710). In some examples, the user can manually adjust these thresholds and limits.
[0136] In some examples, these thresholds may be initial values determined to initiate a patient's aDBS therapy. During this initial period or throughout the therapy, the system may identify patient events (such as the occurrence of symptoms and side effects indicating that aDBS may be more effective) and corresponding sensed signals. As described herein, the system (e.g., programmer 104 and / or IMD 106) may determine a range of values (or even specific thresholds) that may be more effective in treating the patient based on event information including patient events and sensed signal information. The initial period for evaluating the therapy (such as a trial period) may be set on the order of days, weeks, or even months, typical of a patient's routine using aDBS therapy. For example, during the patient's therapy, the evaluation of event information may continue periodically or as needed to further update the thresholds.
[0137] Figure 8This is a conceptual diagram illustrating an example screen 800 for tracking LFP power and stimulation amplitude during aDBS therapy. Screen 800 may present data such as event information, which may include patient events, sensed signal data and / or characteristics, and / or stimulation parameter values (e.g., stimulation amplitude corresponding to the sensed signal). Screen 800 may also enable a user to request automatic selection of a new threshold (or range of threshold values) for an adaptive mode based on stored event information. System 100 may store identified patient events (e.g., symptoms and side effects), sensed LFP signals, and stimulation amplitude values over time during the patient's therapy. This monitoring may be beneficial based on longitudinal (chronic) monitoring of the most common peaks observed during patient events occurring over time while the patient 112 is receiving therapy. Processing circuitry 310 monitors the bioelectrical signal (e.g., LFP) over time and plots the associated power of the signal (e.g., LFP power or LSB value) as a trace 814. In some examples, this data will be stored continuously. In other examples, the data will be stored for time periods corresponding to the respective identified patient events (e.g., events detected by the system or indicated by the user). In some examples, trace 814 is presented in conjunction with the current amplitude 816 of stimulation pulses delivered simultaneously. Hemisphere selector 808 allows the user to switch between signals sensed from different leads in the corresponding hemisphere, and time selector allows the user to switch between different time periods to display data corresponding to different time periods. The user can additionally use timeline 812 to select various timelines within different time periods (e.g., days in a month or different patient events). Drug indicator on 804 and off 806 indicate whether the patient was affected by medication during the time period of the stored data.
[0138] LFP and stimulation amplitude can be sampled at a specific rate (e.g., six times per hour) or in response to the identification of a specific patient event. However, higher or lower sampling rates can be used, depending on data storage capacity. During clinical visits (e.g., post-implantation follow-up visits), user interface 400 can present a snapshot 818 of screen 800 and bioelectrical signal information (e.g., LFP peak or LSB value) stored at the same time as the patient event for clinicians to view. In some examples, user interface 400 can present multiple snapshots of LFP peaks. The user can select boxes in snapshot 818 for adjustments, such as selecting different thresholds using the patient event and / or other events. In other examples, processing circuitry 310 can provide event information prompts to the user to confirm indications of new recommended frequencies for monitoring.
[0139] Screen 800 may display an auto-select button 820 to trigger processing circuitry 310 to reanalyze data (such as event information) to determine a range (or even a specific selected value) of one or more thresholds for subsequent use in the adaptive mode. In this way, the system can re-identify appropriate thresholds using sensed signals during patient events. In some examples, the system may also adjust stimulation parameter limits simultaneously based on the same data. Although screen 800 instructs the user to analyze stored sensed signals for adjusting thresholds in the adaptive mode, processing circuitry 310 may automatically trigger a redetering of thresholds based on any triggering event (such as an LFP signal that does not respond to a change in stimulation, user input indicating ineffective therapy, or even patient events sensed using physiological signals (e.g., patient movement, posture, falls, etc.)) that indicate the therapy is ineffective in treating the patient's symptoms.
[0140] The processing circuit 310 can then control the delivery of subsequent deep brain stimulation based on one or more updated or adjusted thresholds. In any case, the processing circuit 310 can periodically adjust one or more parameters defining adaptive stimulation (e.g., electrode combination, sensing frequency, adaptive mode, adaptive threshold, stimulation threshold, etc.) to maintain therapeutic efficacy. The user can use the off button 822 to turn off the screen 800 to simultaneously save these settings. While the technology has been described using processing circuit 310, other processing circuits, such as processing circuit 210 or a combination of processing circuits 310 and 210, may also be used. Figure 8 It is described as providing sensing data sensed during stimulus delivery, but this sensing data may be sensed at the time of stimulus delivery or during active stimulation periods, but the actual stimulus delivery does not overlap with this sensing data or detected event data. In some examples, the system may sense data and / or events during periods when no stimulation therapy is provided or even separate from any therapy delivery.
[0141] Figure 9 This is a conceptual diagram of an example screen 900 that displays example event information associated with a corresponding patient event. Figure 9 Screen 900 is shown displaying patient events and corresponding LFP information displayed on a coordinate graph 906 of LFP power versus frequency. Trace 912 shows the LFP power for each event shown in event list 914, but in other examples, other characteristic values of the sensed signal, such as different scaling powers (e.g., LSB), can be calculated and displayed. Hemisphere selector 902 is selectable to switch between signals sensed from different leads, and range selector 904 is selectable to switch between different time periods of patient events. While four event types are shown as selectable in this example, in other examples, the user may specify fewer or more types of events. Figure 9 Screen 900 provides a slider 910 that the user can move to adjust the frequency bar 908 and identify the frequency and / or power of any portion of each trace. On the right side of screen 900, an event list 914 is provided for each event. In response to the user deselecting an event (e.g., by unchecking the corresponding checkbox), the user interface 400 removes that particular trace of the event from the coordinate graph 906. This allows the user to select and compare any event. In some examples, the user can choose which patient events to use to determine a range or value, or a specific value, of a threshold. For example, the user can remove any patient events that they do not want to be included in the determination of an updated threshold. In other examples, other types of information for each event can be captured, such as medication status, accelerometer data, stimulus delivery status, etc. Each of these types of information can be presented on the same coordinate graph or a different coordinate graph used for each type of information. Selecting the close button 918 will close screen 900.
[0142] Figure 10 This is a conceptual diagram of a sample screen 1000 that illustrates the display of a single sample patient event and sample-related event information. Figure 10 Example screen 1000 is illustrated, in which movement disorder events are identified and the corresponding trace 1004 is shown in coordinate graph 1002. In some examples, programmer 104 may automatically place frequency bar 908 at the frequency peak, but the user can always move slider 910 to the peak on trace 1004. Using screen 1000, the user can be able to view specific event information for a specific patient event and update various parameters or view specific information used to update thresholds. In this example, movement disorder may be a side effect of stimulation, and the user may want to view the power and / or frequency of the sensed signal corresponding to the sensed side effect.
[0143] Figure 11A and Figure 11B It is a chart of example thresholds and value ranges determined based on event information. For example... Figure 11A As shown in the example, an initial threshold is illustrated in graph 1100. For example, an upper threshold 1104 is shown in relation to a lower threshold 1102. Together, the upper threshold 1104 and the lower threshold 1102 correspond to a steady-state window that can be used by the IMD 106 to deliver aDBS therapy to the patient. The values of the upper threshold 1104 and the lower threshold 1102 are indicated as “LSB,” which is a characteristic of the sensed LFP signal.
[0144] LSB values can be calculated to provide a consistent characteristic of the power of the LFP value sensed at any given time. LSB values can be analogous to the LFP spectral power. However, LSB values can be calculated by averaging the LFP power over multiple time periods (e.g., a "bin" of predetermined time periods) and then summing those powers to provide a representative power over the duration of the multiple time periods. This LSB value can then normalize the LFP signal within a specific time segment that can be compared to other time segments. For example, the LSB value within that time segment better represents the clinically relevant power of the LFP signal compared to the maximum LFP power at a given moment.
[0145] An example method for calculating the LSB (e.g., a characteristic value of the sensed LFP signal) can be performed using the following equation (1): ADC = LFP power ((gain × 2) 15.57 ) / 120000) (1) Where ADC is a scaled value from LFP power, which in some examples may have, for example, The unit of Vp. In a specific example, the gain can be calculated according to the following equation (2): Gain = 250 × (INS fine-tuning value per channel) / (255) (2) The INS fine-tuning value for each channel can be a specific offset of the sensing channel, which can vary for different devices or different channels. The gain can be calibrated as needed. The system can then calculate the ADC value for each chamber (e.g., for each time period of calculating LFP power). The system can then sum over all chambers corresponding to the patient event to determine the LSB value of that LFP snapshot corresponding to the patient event.
[0146] The duration of each LFP snapshot for a patient event can be predetermined. In one example, the duration might be set to 30 seconds, but in some examples, shorter durations of 10 seconds or less can be used, or in other examples, durations of several minutes or longer can be used. The time period for each chamber can also be predetermined. In some examples, a chamber may include the LFP power sensed within a specific time period. An example chamber could have a length of 6 seconds, allowing five chambers to be used to achieve a 30-second duration for LFP snapshots. However, in other examples, shorter or longer duration chambers, as well as fewer or more chambers, can be used. In any case, the system can set the duration and number of chambers for a single patient to enable the system to compare LSB values with different patient events and within the duration of therapy.
[0147] The LFP signal corresponding to a patient event can be an LFP signal that occurs after the patient event is identified, an LFP signal sensed before and after the patient event, or an LFP signal sensed before the patient event. For cases where the patient event begins before the sensing data indicates the patient event, or where the user can input an indication that a patient event is occurring, it may be important to look back at past time periods to find the LFP signal. In this way, the system can store the LFP signals in a buffer, storing LFP signals that occurred previously in response to the detection of a patient event for a specific time period.
[0148] The following data are provided as examples of new value ranges for determining the corresponding thresholds. Table 1 below indicates symptom patient events on the left side of the body, corresponding to brain signals sensed in the right hemisphere. The left column indicates specific patient events, and the right column indicates LSB values calculated based on LFP snapshots associated with the patient events.
[0149]
[0150] Table 1.
[0151] As shown in Table 1 above, the average of the three lowest LSB values is 970. This LSB value corresponds to a threshold level below which an increase in stimulus amplitude may be effectively elicited to alleviate symptoms. In other examples, more or fewer LSB values may be used to calculate the average. A high average LSB can... Figure 11B The threshold range 1114 is shown in Figure 1110, which indicates that the selected upper threshold should be set to be equal to or lower than the threshold range 1114.
[0152] Table 2 below indicates side effect patient events on the left side of the body, corresponding to brain signals sensed in the right hemisphere. The left column indicates specific patient events, and the right column indicates LSB values calculated based on LFP snapshots associated with the patient events.
[0153]
[0154] Table 2.
[0155] As shown in Table 2 above, the average of the three highest LSB values is 471. This LSB value corresponds to a threshold level above which can effectively reduce the stimulus amplitude to mitigate side effects (e.g., movement disorders). In other examples, more or fewer LSB values can be used to calculate the average. A lower average LSB can... Figure 11B The threshold range 1112 is shown in Figure 1110, indicating that the selected lower threshold should be set to be equal to or higher than the threshold range 1112. A similar procedure can be used for any type of adaptive stimulus.
[0156] In some examples, the user can manually determine the desired adjusted upper and lower threshold values within the corresponding threshold ranges 1114 and 1112 (e.g., each threshold is between 1114 and 1112). In other examples, the processing circuitry 310 can automatically select the adjusted thresholds based on a percentage of the LSB threshold range, a percentage of the values between the upper threshold range 1114 and the lower threshold range 1112, or a predetermined value that is above or below the limits of each threshold range 1114 and 1112. The system can do this for each hemisphere, such that one or more thresholds are specific to the sensed values of each hemisphere.
[0157] Figure 12 This is a flowchart illustrating an example technique for determining and displaying a range of values for one or more thresholds defining aDBS therapy. It will be described relative to programmer 104 and processing circuitry 310. Figure 12 Examples of these techniques (and other techniques related to guided programming discussed in this article) are provided. However, some or all of these techniques may alternatively be performed by other devices or systems, such as the IMD 106 or another external device. In some examples, multiple devices may perform these techniques in a distributed manner until completion.
[0158] like Figure 12 As illustrated in the example, the processing circuitry 310 of system 100 may receive event information (1200) representing sensed brain bioelectrical signals (e.g., LFP signals) corresponding to one or more patient events during aDBS therapy. These patient events may include the occurrence of symptoms and / or side effects. In some examples, Figure 12 The technology may include sensing signals or other events that do not occur during therapy delivery. Processing circuitry 310 may then determine a range of values (1202) for at least one threshold defining the aDBS therapy based on the event information and threshold determination instructions. This range may be determined by two constraint values, or a minimum or maximum value, wherein an effective threshold may be equal to or higher than the minimum value or equal to or lower than the maximum value. In some examples, processing circuitry 310 may calculate a normalized LSB value for the LFP power over a given time period, which allows the system to compare LFP signals sensed over different time periods.
[0159] Then, the processing circuit 310 can control (e.g., the programmer 104) the display device to present an indication (1204) of a value range for at least one threshold. Such a range may correspond to Figure 11BThe threshold ranges are 1112 and 1114. The processing circuit 310 can then receive user input via a user interface, where the user input selects a value from a range of values for at least one threshold (1206). The processing circuit 310 can then control the IMD 106 to deliver subsequent aDBS treatments based on the value of at least one threshold (1208). The processing circuit 310 can repeat this process periodically or in response to user input, or detect patient events during treatment to update the thresholds and / or other parameters as needed, thereby improving treatment efficacy.
[0160] In some examples, processing circuitry 310 may be configured to change the upper and / or lower thresholds in response to detected event information indicating that a threshold needs to be changed. Processing circuitry 310 may use a predetermined percentage decrease or increase (e.g., 10%, 20%, 30%, etc.) of the LFP or LSB value to quickly adjust the thresholds. For example, if the LFP power value of the upper threshold is 900 when an event is detected, processing circuitry 310 may reduce the upper threshold by 20% to 720. The new threshold 720 may be better set to adjust the aDBS and prevent the same event from occurring in the future. If the event is detected again, processing circuitry 310 may apply the predetermined percentage decrease again. In other examples, processing circuitry 310 may present a confirmation or recommendation to the user for approval or selection. In some examples, processing circuitry 310 may use a fine-tuning method to automatically adjust the thresholds. If the threshold is still unsuitable after the first adjustment, processing circuitry 310 may use smaller percentages to make smaller iterative adjustments to the threshold until no further events are detected. These smaller adjustments may be made to increase and / or decrease the threshold. In some examples, smaller adjustments can be iteratively reduced by a certain percentage value or reduced to a predetermined increment, such as from 20% to 5%, to 2%, to a minimum increment change of 1%.
[0161] Figure 13 This is a flowchart illustrating an example technique for selecting values for one or more thresholds defining an aDBS therapy based on event information. The description will be relative to programmer 104 and processing circuitry 310. Figure 13 Examples of these techniques (and other techniques related to guided programming discussed in this article) are provided. However, some or all of these techniques may alternatively be performed by other devices or systems, such as the IMD 106 or another external device. In some examples, multiple devices may perform these techniques in a distributed manner until completion.
[0162] like Figure 13As illustrated in the example, the processing circuitry 310 of system 100 may receive event information (1300) representing sensed brain bioelectrical signals (e.g., LFP signals) corresponding to one or more patient events during aDBS therapy. These patient events may include the occurrence of symptoms and / or side effects. In some examples, Figure 13 The technology may include sensing signals or other events that do not occur during therapy delivery. Processing circuitry 310 may then determine a range of values (1302) for at least one threshold defining the aDBS therapy based on the event information and threshold determination instructions. This range may be determined by two constraint values, or a minimum or maximum value, wherein an effective threshold may be equal to or higher than the minimum value or equal to or lower than the maximum value. In some examples, processing circuitry 310 may calculate a normalized LSB value for the LFP power over a given time period, which allows the system to compare LFP signals sensed over different time periods.
[0163] The processing circuit 310 can then automatically select a value from a range of values for at least one threshold (1304). In some examples, the processing circuit 310 can apply the change directly to the threshold. In other examples, the processing circuit 310 can present the selected value of the threshold to a user (e.g., a clinician or patient) for confirmation before updating the therapy. In other examples, the processing circuit 310 can directly select an adjusted value for one or more thresholds without first determining the range of values. The processing circuit 310 can control the IMD 106 to deliver subsequent aDBS therapy based on the value of at least one threshold (1306). The processing circuit 310 can repeat this process periodically or in response to user input, or detect patient events during patient therapy to update the thresholds and / or other parameters as needed, thereby improving therapy efficacy.
[0164] Figure 14 This is a block diagram illustrating example system 1400, which includes components coupled to via network 1486. Figure 1 A to Figure 1External devices (such as server 1482 and one or more computing devices 1484A-1484N) of the IMD 106 and external programmer 104 shown in B. In this example, the IMD 106 can communicate with the external programmer 104 via a first wireless connection using its telemetry circuitry 88, and with the access point 1488 via a second wireless connection. In some examples, system 1400 may include additional devices. For example, system 1400 may also include a communication device 1402, which may be an intermediary device configured to communicate with the IMD 106 via a communication protocol and with the programmer 104 and / or network 1486 using different communication protocols. Communication device 1402 may provide additional functionality, such as recharging functionality for the rechargeable battery of the IMD 106. Communication device 1402 may be referred to as an "intermediary device" and can be used to transfer data between the IMD 106 and network 1486, as well as other servers or computing devices.
[0165] System 1400 may be part of a digital health platform that can share information and perform certain functions between devices, such as sharing information sensed or otherwise obtained by IMD 104 and / or programmer 106 with other remote computing devices, in addition to transmitting updated sensing and / or programming instructions from remote computing devices (such as server 1482 and / or computing devices 1484A-1484N) back to programmer 104 and / or IMD 106.
[0166] exist Figure 14 In the example, access point 1488, external programmer 104, server 1482, and computing devices 1484A-1484N are interconnected via network 1486 and are able to communicate with each other. In some cases, one or more of access point 1488, external programmer 104, server 1482, and computing devices 1484A-1484N may be coupled to network 1486 via one or more wireless connections. IMD 106, external programmer 104, server 1482, and computing devices 1484A-1484N may each include one or more processors capable of performing various functions and operations, such as those described in this disclosure, including one or more microprocessors, digital signal processors (DSPs), application-specific integrated circuits (ASICs), field-programmable gate arrays (FPGAs), programmable logic circuits, etc.
[0167] Access point 1488 may include devices such as home monitoring devices that are connected to network 1486 via any of a variety of connections such as dial-up telephone, digital subscriber line (DSL), cable modem connection, fiber optic communication, etc. In other examples, access point 1488 may be coupled to network 1486 via different forms of connection, including wired or wireless connections.
[0168] During operation, IMD 106 can collect and store various forms of data. For example, IMD 106 can collect sensed electrical signals and / or event data indicative of the efficacy of the therapy and / or the disease state of patient 12 during therapy delivery. In some cases, IMD 106 can directly analyze the collected data to assess patient 12, such as identifying events and / or sensed data. However, in other cases, IMD 106 can wirelessly or via access point 1488 and network 1486 transmit stored data associated with events and / or other sensed data to external programmer 104 and / or server 1482 for remote processing and analysis. For example, IMD 106 can transmit sensed information (such as event data) to computing device 1484A, and computing device 1484A can evaluate the sensed information and generate updated stimulation parameters, event data, or other patient-related information.
[0169] In some cases, server 1482 may be configured to provide a secure storage site for archiving information collected from IMD 106, external programmer 104, or any other device of system 1400. Network 1486 may include a local area network, wide area network, or global network, such as the Internet. In some cases, external programmer 104 or server 1482 may compile sensed data, event data, or other therapeutic information into web pages or other documents for viewing by trained professionals, such as clinicians, via viewing terminals associated with computing devices 1484A-1484N. In this way, system 1400, used as a digital health platform, may enable cloud-based functionality for any of the processes and / or user interactions described herein.
[0170] For example, a user can log in to the digital health platform of system 1400 via one or more devices, such as any of computing devices 1484A-1484N. In one example, a user can log in to the digital health platform using computing device 1484A. The user can interact with a user interface displayed via an internet browser or a specific application. For example, a screen displaying user interface 400 may be present. In relation to the functionality described herein, the platform may provide the user with information related to event data and / or therapy, such as which hemisphere of the brain is associated with a symptom or side effect that has occurred or is occurring, and the LSB value of sensed bioelectrical signals associated with that symptom, side effect, or related event. In some examples, the user interface provided via the digital health platform may include, for example, Figure 11A and Figure 11B The information in Figures 1100 and 1110 is then displayed. The user interface can then be configured to receive user input that approves an update or adjustment of the threshold suggested based on the LSB value. In some examples, the user interface may present additional information about one or more thresholds. For example, the user interface may present information such as: setting the threshold within the range suggested by the LSB value reduces the occurrence of events because the adaptive stimulation therapy will be adjusted based on the updated threshold. The system 1400 can then send the updated threshold back to the IMD 106 via network 1486.
[0171] Furthermore, although this disclosure is described in relation to DBS therapy, such techniques can be applied to IMDs for other therapies where conveying sensing and event data information (such as, for example, spinal cord stimulation (SCS), pelvic floor stimulation, gastric stimulation, occipital nerve stimulation, functional electrical stimulation, etc.) is important. Additionally, in some aspects, techniques for assessing postural status information as described in this disclosure can be applied to IMDs that provide other therapies (e.g., drug pumps), or IMDs that are generally dedicated to sensing or monitoring and do not include stimulation or other therapeutic components.
[0172] The following embodiments are described in this article.
[0173] Example 1. A system includes: processing circuitry configured to: receive sensing data indicating brain bioelectrical signals sensed during delivery of brain stimulation therapy to a patient; receive event data indicating events experienced by the patient during delivery of the brain stimulation therapy; identify a subset of the sensing data based on the event data; determine a value range defining at least one threshold for subsequent brain stimulation therapy based on the subset of the sensing data and the event data, the value range being determined to reduce the occurrence of the event during delivery of the subsequent brain stimulation therapy; and control a medical device to deliver the subsequent brain stimulation therapy according to the at least one threshold within the value range.
[0174] Example 2. The system according to Example 1, wherein the event includes at least one of symptom occurrence or side effect occurrence.
[0175] Example 3. The system according to any one of Examples 1 or 2, wherein the sensed brain bioelectric signal includes a local field potential (LFP) signal, and wherein the information representing the sensed brain signal includes a characteristic value indicating the power of the LFP signal.
[0176] Example 4. The system according to any one of Examples 3, wherein the processing circuit is configured to calculate the characteristic value by at least the following operations: determining the spectral power value of the LFP signal in each of a plurality of time periods; and summing the spectral power from each of the plurality of time periods to calculate the cumulative power corresponding to the event.
[0177] Example 5. The system according to any one of Examples 1 to 4, wherein the processing circuit is configured to: determine a value within the value range of the at least one threshold based on the event data and the sensing data; and control the medical device to deliver the subsequent brain stimulation therapy according to the value.
[0178] Example 6. The system according to any one of Examples 1 to 5, wherein the processing circuit is configured to: control the display device to present the value range via a user interface; receive user input via the user interface to select a value within the range of the at least one threshold; and control the medical device to deliver the subsequent brain stimulation therapy according to the value of the at least one threshold.
[0179] Example 7. The system according to any one of Examples 1 to 6, wherein the at least one threshold includes an upper threshold and a lower threshold defining the brain stimulation therapy and the subsequent brain stimulation therapy.
[0180] Example 8. The system according to any one of Examples 1 to 7, wherein the event data includes value data of stimulation parameters corresponding to sensed brain bioelectric signals, and wherein the processing circuit is configured to determine one or more limits of the stimulation parameters that at least partially define the subsequent brain stimulation therapy based on the event data.
[0181] Example 9. The system according to any one of Examples 1 to 8, the system further includes an external programmer that includes the processing circuitry.
[0182] Example 10. The system according to any one of Examples 1 to 9, the system further includes the medical device, wherein the medical device is configured to be implanted in the patient.
[0183] Example 11. A method comprising: receiving, by processing circuitry, sensing data indicating brain bioelectrical signals sensed during delivery of brain stimulation therapy to a patient; receiving, by processing circuitry, event data indicating events experienced by the patient during delivery of the brain stimulation therapy; identifying, by processing circuitry, a subset of the sensing data based on the event data; determining, by processing circuitry, a value range defining at least one threshold for subsequent brain stimulation therapy based on the subset of the sensing data and the event data, the value range being determined to reduce the occurrence of the event during delivery of the subsequent brain stimulation therapy; and controlling, by processing circuitry, a medical device to deliver the subsequent brain stimulation therapy according to the at least one threshold within the value range.
[0184] Example 12. The method according to Example 11, wherein the event includes at least one of symptom occurrence or side effect occurrence.
[0185] Example 13. The method according to any one of Examples 11 or 12, wherein the sensed brain bioelectric signal includes a local field potential (LFP) signal, and wherein the information representing the sensed brain signal includes a characteristic value indicating the power of the LFP signal.
[0186] Example 14. The method according to any one of Examples 13, wherein calculating the characteristic value includes: determining the spectral power value of the LFP signal in each of a plurality of time periods; and summing the spectral power from each of the plurality of time periods to calculate the cumulative power corresponding to the event.
[0187] Example 15. The method according to any one of Examples 11 to 14, further comprising: determining a value within the value range of the at least one threshold based on the event data and the sensing data; and controlling the medical device to deliver the subsequent brain stimulation therapy according to the value.
[0188] Example 16. The method according to any one of Examples 11 to 15, further comprising: controlling a display device to present the value range via a user interface; receiving user input via the user interface to select a value within the range of the at least one threshold; and controlling the medical device to deliver the subsequent brain stimulation therapy according to the value of the at least one threshold.
[0189] Example 17. The method according to any one of Examples 11 to 16, wherein the at least one threshold includes an upper threshold and a lower threshold defining the brain stimulation therapy and the subsequent brain stimulation therapy.
[0190] Example 18. The method according to any one of Examples 11 to 17, wherein the event data includes value data of stimulation parameters corresponding to sensed brain bioelectric signals, and wherein the method further includes determining one or more limits of the stimulation parameters that at least partially define the subsequent brain stimulation therapy based on the event data.
[0191] Example 19. The method according to any one of Examples 11 to 18, wherein the external programmer includes the processing circuitry.
[0192] Example 20. A non-transitory computer-readable medium including instructions that, when executed, control processing circuitry to: receive sensing data indicating brain bioelectrical signals sensed during delivery of brain stimulation therapy to a patient; receive event data indicating events experienced by the patient during delivery of the brain stimulation therapy; identify a subset of the sensing data based on the event data; determine a value range defining at least one threshold for subsequent brain stimulation therapy based on the subset of the sensing data and the event data, the value range being determined to reduce the occurrence of the event during delivery of the subsequent brain stimulation therapy; and control a medical device to deliver the subsequent brain stimulation therapy according to the at least one threshold within the value range.
[0193] The techniques described in this disclosure may be implemented, at least in part, in hardware, software, firmware, or any combination thereof, including those attributable to the IMD 106, programmer 104, or various component parts. For example, aspects of these techniques may be implemented within one or more processors, including one or more microprocessors, DSPs, ASICs, FPGAs, or any other equivalent integrated or discrete logic circuits, and any combination of such components embodied in a programmer, such as a clinician or patient programmer, medical device, or other device.
[0194] In one or more examples, the functionality described in this disclosure may be implemented in hardware, software, firmware, or any combination thereof. If implemented in software, the functionality may be stored as one or more instructions or code on a computer-readable medium and executed by a hardware-based processing unit. The computer-readable medium may include a computer-readable storage medium forming a tangible, non-transitory medium. The instructions may be executed by one or more processors, such as one or more DSPs, ASICs, FPGAs, general-purpose microprocessors, or other equivalent integrated or discrete logic circuits. Therefore, the term "processor" as used herein may refer to one or more of the foregoing structures or any other structures suitable for implementing the techniques described herein.
[0195] In addition, in some aspects, the functionality described herein may be provided within dedicated hardware and / or software modules. Describing different features as modules or units is intended to highlight different functional aspects and does not necessarily imply that such modules or units must be implemented by separate hardware or software components. Rather, the functionality associated with one or more modules or units may be performed by separate hardware or software components, or integrated into common or separate hardware or software components. Furthermore, this technology may be fully implemented in one or more circuit or logic elements. The technology disclosed herein can be implemented in a variety of devices or apparatuses, including IMDs, external programmers, combinations of IMDs and external programmers, integrated circuits (ICs), or a set of ICs and / or discrete circuits residing in IMDs and / or external programmers.
[0196] Various embodiments have been described. These and other embodiments are within the scope of the appended claims.
Claims
1. A system comprising: Processing circuit, the processing circuit being configured to: Receive sensing data indicating brain bioelectrical signals sensed during the delivery of brain stimulation therapy to the patient; Receive event data indicating events experienced by the patient during the delivery of the brain stimulation therapy; A subset of the sensed data is identified based on the event data; Based on the subset of the sensed data and the event data, a value range is determined to define at least one threshold for subsequent brain stimulation therapy, the value range being determined to reduce the occurrence of the event during the delivery of the subsequent brain stimulation therapy; as well as The medical device is controlled to deliver the subsequent brain stimulation therapy according to at least one threshold within the range of said values.
2. The system of claim 1, wherein the event includes at least one of symptom occurrence or side effect occurrence.
3. The system according to any one of claims 1 or 2, wherein the sensed brain bioelectric signal includes a local field potential (LFP) signal, and wherein information representing the sensed brain signal includes characteristic values indicating the power of the LFP signal.
4. The system according to any one of claims 3, wherein the processing circuitry is configured to calculate the characteristic value by at least the following operations: Determine the spectral power value of the LFP signal in each of the multiple time periods; and The spectral power from each of the plurality of time periods is summed to calculate the cumulative power corresponding to the event.
5. The system according to any one of claims 1 to 4, wherein the processing circuit is configured to: Based on the event data and the sensed data, determine a value within the value range of the at least one threshold; and The medical device is controlled to deliver the subsequent brain stimulation therapy according to the value.
6. The system according to any one of claims 1 to 5, wherein the processing circuit is configured to: The control display device presents the value range via a user interface; Receive user input via the user interface to select a value within the range of the at least one threshold; and The medical device is controlled to deliver the subsequent brain stimulation therapy according to the value of the at least one threshold.
7. The system according to any one of claims 1 to 6, wherein the at least one threshold includes an upper threshold and a lower threshold defining the brain stimulation therapy and the subsequent brain stimulation therapy.
8. The system according to any one of claims 1 to 7, wherein the event data includes value data of stimulation parameters corresponding to sensed brain bioelectrical signals, and wherein the processing circuitry is configured to determine one or more limits of the stimulation parameters that at least partially define the subsequent brain stimulation therapy based on the event data.
9. The system according to any one of claims 1 to 8, the system further comprising an external programmer, the external programmer including the processing circuitry.
10. The system according to any one of claims 1 to 9, the system further comprising the medical device, wherein the medical device is configured to be implanted in the patient.
11. The system according to any one of claims 1 to 10, the system further comprising a sensing circuit configured to sense the brain bioelectrical signal.
12. The system according to any one of claims 1 to 11, the system further comprising a stimulation circuit configured to deliver the brain stimulation therapy and the subsequent brain stimulation therapy.
13. A non-transitory computer-readable medium comprising instructions that, when executed, control the processing circuitry to perform the function according to any one of claims 1 to 12.
Citation Information
Patent Citations
Medical service employing multiple DC accelerometers for patient activity and posture sensing and method
US5593431A
